Transcriptional	O
and	O
posttranscriptional	O
regulation	O
of	O
erythroid	B-DNA
gene	I-DNA
expression	O
in	O
anthracycline-induced	O
differentiation	O
of	O
human	B-cell_type
erythroleukemic	I-cell_type
cells	I-cell_type
.	O

Aclacinomycin	O
(	O
ACLA	O
)	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
were	O
used	O
at	O
subtoxic	O
concentrations	O
to	O
induce	O
erythroid	O
differentiation	O
in	O
the	O
human	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
line	I-cell_line
K562	I-cell_line
.	O

Cell	O
hemoglobinization	O
was	O
accompanied	O
by	O
the	O
increased	O
expression	O
of	O
genes	B-DNA
encoding	O
gamma-globin	B-protein
and	I-protein
porphobilinogen	I-protein
deaminase	I-protein
(	O
PBGD	B-protein
)	O
,	O
an	O
enzyme	O
of	O
heme	O
synthesis	O
.	O

By	O
using	O
run-on	O
assays	O
,	O
ACLA	O
was	O
shown	O
to	O
induce	O
an	O
enhancement	O
of	O
the	O
transcription	O
of	O
erythroid	B-DNA
genes	I-DNA
,	O
including	O
gamma-globin	B-protein
,	O
PBGD	B-protein
,	O
erythropoietin	B-protein
receptor	I-protein
,	O
and	O
GATA-1	B-protein
transcription	B-protein
factor	I-protein
.	O

In	O
contrast	O
,	O
in	O
DOX-treated	B-cell_line
cells	I-cell_line
,	O
the	O
transcription	O
rate	O
of	O
these	O
genes	B-DNA
was	O
unchanged	O
in	O
comparison	O
with	O
control	B-cell_type
cells	I-cell_type
.	O

In	O
addition	O
,	O
inhibition	O
of	O
mRNA	B-RNA
synthesis	O
with	O
actinomycin	O
D	O
indicated	O
that	O
DOX	O
induced	O
an	O
increased	O
stability	O
of	O
PBGD	B-RNA
and	I-RNA
GATA-1	I-RNA
mRNAs	I-RNA
,	O
whereas	O
ACLA	O
did	O
not	O
affect	O
the	O
half-lives	O
of	O
these	O
mRNAs	B-RNA
.	O

Because	O
the	O
increase	O
in	O
erythroid	B-RNA
mRNA	I-RNA
steady-state	O
level	O
in	O
anthracycline-treated	B-cell_type
cells	I-cell_type
was	O
inhibited	O
by	O
cycloheximide	O
,	O
this	O
suggests	O
that	O
transcriptional	O
activation	O
in	O
ACLA-treated	B-cell_line
cells	I-cell_line
and	O
mRNA	O
stabilization	O
in	O
DOX-treated	B-cell_type
cells	I-cell_type
were	O
dependent	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O

Finally	O
,	O
GATA-1	B-protein
protein	O
level	O
was	O
shown	O
to	O
be	O
increased	O
in	O
ACLA-treated	B-cell_line
but	I-cell_line
not	I-cell_line
in	I-cell_line
DOX-treated	I-cell_line
cells	I-cell_line
.	O

These	O
two	O
anthracyclines	O
,	O
although	O
closely	O
related	O
in	O
their	O
structures	O
,	O
appeared	O
to	O
act	O
as	O
differentiation	O
inducers	O
by	O
distinct	O
mechanisms	O
.	O

Indeed	O
,	O
erythroid	B-DNA
gene	I-DNA
expression	O
was	O
demonstrated	O
to	O
be	O
regulated	O
transcriptionally	O
by	O
ACLA	O
and	O
mainly	O
posttranscriptionally	O
by	O
DOX	O
.	O

Vol	NULL
.	NULL

7	NULL
,	NULL
1023-1029	NULL
,	NULL
August	NULL
1996	NULL
Cell	NULL
Growth	NULL
&	NULL
Differentiation	NULL
Transcriptional	NULL
and	NULL
Posttranscriptional	NULL
Regulation	NULL
of	NULL
Erythroid	NULL
Gene	NULL
Expression	NULL
in	NULL
Anthracycline-induced	NULL
Differentiation	NULL
of	NULL
Human	NULL
Erythroleukemic	NULL
Cells	NULL
'	NULL
Franck	NULL
Morceau	NULL
,	NULL
``	NULL
Benoit	NULL
Chénais	NULL
,	NULL
Reynald	NULL
Gillet	NULL
,	NULL
``	NULL
Jean-Claude	NULL
Jardillier	NULL
,	NULL
Pierre	NULL
Jeannesson	NULL
,	NULL
and	NULL
Chantal	NULL
Trentesaux*	NULL
Laboratoire	NULL
de	NULL
Biochimie	NULL
et	NULL
Biologie	NULL
Moléculaire	NULL
,	NULL
Faculte	NULL
de	NULL
Pharmacie	NULL
,	NULL
Université	NULL
de	NULL
Reims	NULL
Champagne-Ardenne	NULL
,	NULL
51	NULL
Rue	NULL
Cognacq-Jay	NULL
,	NULL
F-51096	NULL
Reims	NULL
Cedex	NULL
,	NULL
France	NULL
Abstract	NULL
Aclacinomycin	NULL
(	NULL
ACLA	NULL
)	NULL
and	NULL
doxorubicin	NULL
(	NULL
DOX	NULL
)	NULL
were	NULL
used	NULL
at	NULL
subtoxic	NULL
concentrations	NULL
to	NULL
induce	NULL
erythroid	NULL
differentiation	NULL
in	NULL
the	NULL
human	NULL
leukemic	NULL
cell	NULL
line	NULL
K562	NULL
.	NULL

Cell	NULL
hemoglobinization	NULL
was	NULL
accompanied	NULL
by	NULL
the	NULL
increased	NULL
expression	NULL
of	NULL
genes	NULL
encoding	NULL
y-globin	NULL
and	NULL
porphobilinogen	NULL
deaminase	NULL
(	NULL
PBGD	NULL
)	NULL
,	NULL
an	NULL
enzyme	NULL
of	NULL
heme	NULL
synthesis	NULL
.	NULL

By	NULL
using	NULL
run-on	NULL
assays	NULL
,	NULL
ACLA	NULL
was	NULL
shown	NULL
to	NULL
induce	NULL
an	NULL
enhancement	NULL
of	NULL
the	NULL
transcription	NULL
of	NULL
erythroid	NULL
genes	NULL
,	NULL
including	NULL
y-globin	NULL
,	NULL
PBGD	NULL
,	NULL
erythropoietin	NULL
receptor	NULL
,	NULL
and	NULL
GATA-1	NULL
transcription	NULL
factor	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
DOX-treated	NULL
cells	NULL
,	NULL
the	NULL
transcription	NULL
rate	NULL
of	NULL
these	NULL
genes	NULL
was	NULL
unchanged	NULL
in	NULL
comparison	NULL
with	NULL
control	NULL
cells	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
inhibition	NULL
of	NULL
mRNA	NULL
synthesis	NULL
with	NULL
actinomycin	NULL
D	NULL
indicated	NULL
that	NULL
DOX	NULL
induced	NULL
an	NULL
increased	NULL
stability	NULL
of	NULL
PBGD	NULL
and	NULL
GATA-1	NULL
mRNAs	NULL
,	NULL
whereas	NULL
ACLA	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
half-lives	NULL
of	NULL
these	NULL
mRNAs	NULL
.	NULL

Because	NULL
the	NULL
increase	NULL
in	NULL
erythroid	NULL
mRNA	NULL
steady-state	NULL
level	NULL
in	NULL
anthracycline-treated	NULL
cells	NULL
was	NULL
inhibited	NULL
by	NULL
cycloheximide	NULL
,	NULL
this	NULL
suggests	NULL
that	NULL
transcriptional	NULL
activation	NULL
in	NULL
ACLA-treated	NULL
cells	NULL
and	NULL
mRNA	NULL
stabilization	NULL
in	NULL
DOX-treated	NULL
cells	NULL
were	NULL
dependent	NULL
on	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
.	NULL

Finally	NULL
,	NULL
GATA-1	NULL
protein	NULL
level	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
increased	NULL
in	NULL
ACLA-treated	NULL
but	NULL
not	NULL
in	NULL
DOX-treated	NULL
cells	NULL
.	NULL

These	NULL
two	NULL
anthracyclines	NULL
,	NULL
although	NULL
closely	NULL
related	NULL
in	NULL
their	NULL
structures	NULL
,	NULL
appeared	NULL
to	NULL
act	NULL
as	NULL
differentiation	NULL
inducers	NULL
by	NULL
distinct	NULL
mechanisms	NULL
.	NULL

Indeed	NULL
,	NULL
erythroid	NULL
gene	NULL
expression	NULL
was	NULL
demonstrated	NULL
to	NULL
be	NULL
regulated	NULL
transcriptionally	NULL
by	NULL
ACLA	NULL
and	NULL
mainly	NULL
posttranscriptionally	NULL
by	NULL
DOX	NULL
.	NULL

Received	NULL
1/22/96	NULL
;	NULL
revised	NULL
4/23/96	NULL
;	NULL
accepted	NULL
6/5/96	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Association	NULL
pour	NULL
la	NULL
Recherche	NULL
sur	NULL
le	NULL
Cancer	NULL
(	NULL
6354	NULL
)	NULL
and	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Ligue	NULL
Nationale	NULL
Contre	NULL
le	NULL
Cancer	NULL
,	NULL
comité	NULL
de	NULL
l'Aisne	NULL
.	NULL

2	NULL
Recipient	NULL
of	NULL
a	NULL
fellowship	NULL
from	NULL
the	NULL
Ligue	NULL
Nationale	NULL
Contre	NULL
le	NULL
Cancer	NULL
,	NULL
comité	NULL
de	NULL
la	NULL
Marne	NULL
.	NULL

*	NULL
Recipient	NULL
of	NULL
a	NULL
fellowship	NULL
from	NULL
the	NULL
Ministére	NULL
de	NULL
|'Enseignement	NULL
Supérieur	NULL
et	NULL
de	NULL
la	NULL
Recherche	NULL
.	NULL

*	NULL
To	NULL
whom	NULL
requests	NULL
for	NULL
reprints	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

Phone	NULL
:	NULL
33-26-05-35-67	NULL
;	NULL
Fax	NULL
:	NULL
33-26-05-37-30	NULL
.	NULL

Introduction	NULL
Because	NULL
malignant	NULL
cells	NULL
are	NULL
blocked	NULL
in	NULL
their	NULL
normal	NULL
maturation	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
differentiation	NULL
of	NULL
tumor	NULL
cells	NULL
may	NULL
provide	NULL
an	NULL
alternative	NULL
or	NULL
support	NULL
to	NULL
conventional	NULL
cytotoxic	NULL
chemotherapy	NULL
of	NULL
cancer	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

In	NULL
this	NULL
respect	NULL
,	NULL
numerous	NULL
studies	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
have	NULL
been	NULL
undertaken	NULL
using	NULL
a	NULL
broad	NULL
range	NULL
of	NULL
chemical	NULL
differentiating	NULL
agents	NULL
,	NULL
including	NULL
retinoic	NULL
acid	NULL
(	NULL
4-6	NULL
)	NULL
,	NULL
butyrate	NULL
derivatives	NULL
(	NULL
7	NULL
)	NULL
,	NULL
DMSO	NULL
(	NULL
4	NULL
)	NULL
,	NULL
and	NULL
anthracyclines	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Among	NULL
these	NULL
models	NULL
,	NULL
the	NULL
best	NULL
characterized	NULL
is	NULL
probably	NULL
the	NULL
all-trans-retinoic	NULL
acid-mediated	NULL
differentiation	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
,	NULL
both	NULL
at	NULL
experimental	NULL
and	NULL
clinical	NULL
levels	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
.	NULL

Anthracycline	NULL
antitumor	NULL
antibiotics	NULL
such	NULL
as	NULL
ACLA®	NULL
and	NULL
DOX	NULL
are	NULL
widely	NULL
used	NULL
in	NULL
conventional	NULL
cancer	NULL
chemotherapy	NULL
,	NULL
and	NULL
their	NULL
cytotoxic	NULL
effects	NULL
are	NULL
commonly	NULL
accepted	NULL
to	NULL
be	NULL
due	NULL
to	NULL
DNA	NULL
intercalation	NULL
(	NULL
9	NULL
)	NULL
and	NULL
interaction	NULL
with	NULL
the	NULL
nuclear	NULL
enzyme	NULL
type	NULL
II	NULL
DNA	NULL
topoisomerase	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Anthracyclines	NULL
have	NULL
also	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
potent	NULL
differentiation	NULL
inducers	NULL
,	NULL
when	NULL
used	NULL
at	NULL
subtoxic	NULL
concentrations	NULL
,	NULL
in	NULL
numerous	NULL
experimental	NULL
systems	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
most	NULL
of	NULL
these	NULL
approaches	NULL
describe	NULL
the	NULL
appearance	NULL
either	NULL
of	NULL
morphological	NULL
changes	NULL
or	NULL
differentiation	NULL
markers	NULL
but	NULL
remain	NULL
unclear	NULL
on	NULL
the	NULL
molecular	NULL
basis	NULL
of	NULL
these	NULL
effects	NULL
.	NULL

Previous	NULL
studies	NULL
using	NULL
erythroleukemia	NULL
cell	NULL
lines	NULL
(	NULL
MEL	NULL
cells	NULL
and	NULL
human	NULL
KMOE	NULL
and	NULL
K562	NULL
cell	NULL
lines	NULL
)	NULL
have	NULL
demonstrated	NULL
that	NULL
ACLA	NULL
and	NULL
DOX	NULL
,	NULL
at	NULL
subtoxic	NULL
concentrations	NULL
,	NULL
are	NULL
able	NULL
to	NULL
induce	NULL
the	NULL
appearance	NULL
of	NULL
hemoglobin-producing	NULL
cells	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Using	NULL
the	NULL
human	NULL
KS562	NULL
cell	NULL
line	NULL
as	NULL
a	NULL
model	NULL
of	NULL
erythroid	NULL
differentiation	NULL
,	NULL
we	NULL
reported	NULL
earlier	NULL
that	NULL
DOX-	NULL
and	NULL
ACLA-induced	NULL
cell	NULL
hemoglobinization	NULL
was	NULL
accompanied	NULL
by	NULL
an	NULL
increased	NULL
expression	NULL
of	NULL
globin	NULL
genes	NULL
(	NULL
11	NULL
)	NULL
and	NULL
induction	NULL
of	NULL
EPOR	NULL
expression	NULL
(	NULL
12	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

Moreover	NULL
,	NULL
we	NULL
recently	NULL
described	NULL
that	NULL
both	NULL
ACLA	NULL
and	NULL
DOX	NULL
induced	NULL
an	NULL
increase	NULL
in	NULL
y-globin	NULL
and	NULL
PBGD	NULL
mRNA	NULL
levels	NULL
,	NULL
whereas	NULL
EPOR	NULL
mRNA	NULL
was	NULL
enhanced	NULL
only	NULL
in	NULL
ACLA-treated	NULL
cells	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Because	NULL
erythroid-specific	NULL
transcription	NULL
factors	NULL
,	NULL
especially	NULL
GATA-1	NULL
and	NULL
NF-E2	NULL
,	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
play	NULL
a	NULL
central	NULL
role	NULL
in	NULL
the	NULL
control	NULL
of	NULL
erythroid	NULL
gene	NULL
promoters	NULL
(	NULL
14	NULL
,	NULL
15	NULL
)	NULL
,	NULL
they	NULL
could	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
anthracycline-induced	NULL
differentiation	NULL
process	NULL
.	NULL

The	NULL
major	NULL
erythroid	NULL
DNA-binding	NULL
protein	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
GATA-1	NULL
,	NULL
recognizes	NULL
the	NULL
sequence	NULL
(	NULL
A/T	NULL
)	NULL
GATA	NULL
(	NULL
A/G	NULL
)	NULL
,	NULL
which	NULL
has	NULL
been	NULL
found	NULL
in	NULL
the	NULL
regulatory	NULL
domains	NULL
of	NULL
several	NULL
erythroid-specific	NULL
genes	NULL
(	NULL
14	NULL
)	NULL
,	NULL
including	NULL
globins	NULL
(	NULL
16	NULL
)	NULL
,	NULL
EPOR	NULL
(	NULL
17	NULL
)	NULL
,	NULL
PBGD	NULL
(	NULL
18	NULL
)	NULL
,	NULL
and	NULL
interestingly	NULL
,	NULL
GATA-1	NULL
itself	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Convincing	NULL
evidence	NULL
for	NULL
the	NULL
central	NULL
role	NULL
of	NULL
GATA-1	NULL
in	NULL
regulating	NULL
eryth-ropoiesis	NULL
has	NULL
been	NULL
provided	NULL
by	NULL
disrupting	NULL
this	NULL
locus	NULL
via	NULL
®	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
ACLA	NULL
,	NULL
aclacinomycin	NULL
;	NULL
CHX	NULL
,	NULL
cycloheximide	NULL
;	NULL
DOX	NULL
,	NULL
doxorubicin	NULL
;	NULL
EPOR	NULL
,	NULL
erythropoietin	NULL
receptor	NULL
;	NULL
GAPDH	NULL
,	NULL
glyceralde-hyde-3-phosphate	NULL
dehydrogenase	NULL
;	NULL
MEL	NULL
,	NULL
murine	NULL
eythroleukemia	NULL
;	NULL
PBGD	NULL
,	NULL
porphobilinogen	NULL
deaminase	NULL
.	NULL

1024	NULL
-	NULL
Regulation	NULL
of	NULL
Erythroid	NULL
Gene	NULL
Expression	NULL
by	NULL
Anthracyclines	NULL
homologous	NULL
recombination	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Besides	NULL
,	NULL
native	NULL
NF-E2	NULL
is	NULL
an	NULL
obligate	NULL
heterodimer	NULL
of	NULL
two	NULL
basic	NULL
leucine	NULL
zipper	NULL
proteins	NULL
,	NULL
p45	NULL
and	NULL
p18	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
p45	NULL
is	NULL
largely	NULL
restricted	NULL
to	NULL
hematopoietic	NULL
tissue	NULL
(	NULL
15	NULL
)	NULL
,	NULL
whereas	NULL
p18	NULL
is	NULL
widely	NULL
expressed	NULL
and	NULL
belongs	NULL
to	NULL
v-maf-related	NULL
proteins	NULL
(	NULL
21	NULL
)	NULL
.	NULL

The	NULL
AP-1-related	NULL
transcription	NULL
factor	NULL
NF-E2	NULL
recognizes	NULL
an	NULL
extended	NULL
AP-1	NULL
site	NULL
,	NULL
(	NULL
T/C	NULL
)	NULL
TGCTGA	NULL
(	NULL
C/G	NULL
)	NULL
TCA	NULL
(	NULL
T/C	NULL
)	NULL
,	NULL
initially	NULL
characterized	NULL
in	NULL
the	NULL
PBGD	NULL
gene	NULL
promoter	NULL
(	NULL
18	NULL
)	NULL
and	NULL
in	NULL
the	NULL
locus	NULL
control	NULL
region	NULL
of	NULL
human	NULL
B-globin	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Such	NULL
a	NULL
critical	NULL
role	NULL
of	NULL
erythroid	NULL
transcription	NULL
factors	NULL
GATA-1	NULL
and	NULL
NF-E2	NULL
in	NULL
the	NULL
anthracycline-induced	NULL
differentiation	NULL
was	NULL
evoked	NULL
in	NULL
our	NULL
preliminary	NULL
results	NULL
,	NULL
which	NULL
showed	NULL
that	NULL
ACLA	NULL
induced	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
binding	NULL
capacity	NULL
of	NULL
either	NULL
GATA-1	NULL
or	NULL
NF-E2	NULL
to	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
y-globin	NULL
or	NULL
PBGD	NULL
gene	NULL
,	NULL
respectively	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
expression	NULL
of	NULL
GATA-1	NULL
and	NULL
NF-E2	NULL
mRNA	NULL
was	NULL
increased	NULL
in	NULL
ACLA-treated	NULL
cells	NULL
(	NULL
13	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
DOX	NULL
treatment	NULL
of	NULL
cells	NULL
did	NULL
not	NULL
significantly	NULL
affect	NULL
the	NULL
level	NULL
of	NULL
erythroid-specific	NULL
transcription	NULL
factor	NULL
expression	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Such	NULL
data	NULL
led	NULL
us	NULL
to	NULL
hypothesize	NULL
that	NULL
ACLA	NULL
and	NULL
DOX	NULL
may	NULL
induce	NULL
erythroid	NULL
differentiation	NULL
by	NULL
distinct	NULL
mechanisms	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
present	NULL
report	NULL
compares	NULL
drug	NULL
effects	NULL
on	NULL
both	NULL
transcriptional	NULL
and	NULL
posttranscriptional	NULL
events	NULL
occurring	NULL
when	NULL
cells	NULL
are	NULL
induced	NULL
to	NULL
differentiate	NULL
.	NULL

Results	NULL
indicate	NULL
that	NULL
ACLA	NULL
up-regulated	NULL
the	NULL
transcription	NULL
of	NULL
erythroid	NULL
genes	NULL
(	NULL
y-globin	NULL
,	NULL
PBGD	NULL
,	NULL
and	NULL
EPOAR	NULL
)	NULL
in	NULL
a	NULL
protein	NULL
synthesis-dependent	NULL
way	NULL
,	NULL
without	NULL
affecting	NULL
RNA	NULL
stability	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
DOX	NULL
increased	NULL
stability	NULL
of	NULL
erythroid	NULL
transcripts	NULL
without	NULL
any	NULL
apparent	NULL
effect	NULL
on	NULL
transcriptional	NULL
activity	NULL
.	NULL

These	NULL
results	NULL
clearly	NULL
show	NULL
that	NULL
each	NULL
anthracycline	NULL
enhanced	NULL
erythroid-specific	NULL
gene	NULL
expression	NULL
by	NULL
unrelated	NULL
mechanisms	NULL
despite	NULL
their	NULL
closely	NULL
related	NULL
structures	NULL
.	NULL

Results	NULL
Increased	NULL
Transcription	NULL
of	NULL
Erythroid	NULL
Genes	NULL
in	NULL
ACLA-	NULL
but	NULL
not	NULL
DOX-treated	NULL
Cells	NULL
.	NULL

The	NULL
progressive	NULL
increase	NULL
of	NULL
y-globin	NULL
and	NULL
PBGD	NULL
mRNAs	NULL
during	NULL
ACLA-	NULL
and	NULL
DOX-induced	NULL
differentiation	NULL
of	NULL
K562	NULL
cells	NULL
has	NULL
already	NULL
been	NULL
reported	NULL
in	NULL
our	NULL
previous	NULL
work	NULL
and	NULL
was	NULL
maximal	NULL
at	NULL
day	NULL
3	NULL
after	NULL
induction	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
an	NULL
increase	NULL
of	NULL
EPOR	NULL
,	NULL
NF-E2	NULL
,	NULL
and	NULL
GATA-1	NULL
mRNAs	NULL
was	NULL
observed	NULL
in	NULL
ACLA-	NULL
but	NULL
not	NULL
DOX-treated	NULL
cells	NULL
(	NULL
13	NULL
)	NULL
.	NULL

These	NULL
results	NULL
prompted	NULL
us	NULL
to	NULL
investigate	NULL
the	NULL
effects	NULL
of	NULL
both	NULL
anthracyclines	NULL
regarding	NULL
transcriptional	NULL
activity	NULL
.	NULL

Therefore	NULL
,	NULL
nuclear	NULL
run-on	NULL
experiments	NULL
were	NULL
performed	NULL
using	NULL
isolated	NULL
nuclei	NULL
from	NULL
uninduced	NULL
and	NULL
anthracycline-induced	NULL
K562	NULL
cells	NULL
.	NULL

Treatment	NULL
of	NULL
cells	NULL
with	NULL
20	NULL
nm	NULL
ACLA	NULL
or	NULL
40	NULL
nm	NULL
DOX	NULL
for	NULL
48	NULL
h	NULL
led	NULL
to	NULL
the	NULL
appearance	NULL
of	NULL
51	NULL
and	NULL
43	NULL
%	NULL
of	NULL
benzidine-positive	NULL
cells	NULL
,	NULL
respectively	NULL
,	NULL
versus	NULL
<	NULL
5	NULL
%	NULL
in	NULL
control	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
the	NULL
transcription	NULL
of	NULL
erythroid	NULL
genes	NULL
was	NULL
markedly	NULL
enhanced	NULL
in	NULL
nuclei	NULL
from	NULL
ACLA-treated	NULL
cells	NULL
.	NULL

A	NULL
2-fold	NULL
increase	NULL
in	NULL
EPOR	NULL
and	NULL
PBGD	NULL
gene	NULL
transcription	NULL
was	NULL
observed	NULL
,	NULL
whereas	NULL
the	NULL
increase	NULL
in	NULL
y-globin	NULL
gene	NULL
transcription	NULL
was	NULL
slightly	NULL
higher	NULL
(	NULL
3.6-fold	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
transcription	NULL
of	NULL
erythroid	NULL
transcription	NULL
factor	NULL
GATA-1	NULL
was	NULL
also	NULL
increased	NULL
(	NULL
5-fold	NULL
)	NULL
in	NULL
ACLA-treated	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
transcription	NULL
level	NULL
of	NULL
y-globin	NULL
,	NULL
PBGD	NULL
,	NULL
and	NULL
EPOR	NULL
genes	NULL
remained	NULL
largely	NULL
unchanged	NULL
in	NULL
nuclei	NULL
from	NULL
DOX-treated	NULL
cells	NULL
in	NULL
comparison	NULL
with	NULL
the	NULL
basal	NULL
transcriptional	NULL
level	NULL
of	NULL
these	NULL
genes	NULL
in	NULL
control	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

However	NULL
,	NULL
Control	NULL
ACLA	NULL
DOX	NULL
EPOR	NULL
PBGD	NULL
y-globin	NULL
GATA-1	NULL
GAPDH	NULL
pGEM7	NULL
Bluescript	NULL
G	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Erythroid	NULL
gene	NULL
transcription	NULL
in	NULL
ACLA-	NULL
and	NULL
DOX-treated	NULL
cells	NULL
.	NULL

Nuclei	NULL
were	NULL
isolated	NULL
from	NULL
cells	NULL
grown	NULL
for	NULL
48	NULL
h	NULL
in	NULL
medium	NULL
alone	NULL
(	NULL
Contro	NULL
!	NULL
)	NULL

or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
20	NULL
nm	NULL
ACLA	NULL
or	NULL
40	NULL
nm	NULL
DOX	NULL
.	NULL

Nuclear	NULL
run-on	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
,	NULL
``	NULL
and	NULL
equal	NULL
amounts	NULL
of	NULL
radiolabeled	NULL
mRNA	NULL
were	NULL
hybridized	NULL
onto	NULL
the	NULL
indicated	NULL
DNA	NULL
probes	NULL
;	NULL
pGEM-7	NULL
and	NULL
Bluescript	NULL
plasmid	NULL
vectors	NULL
were	NULL
used	NULL
as	NULL
negative	NULL
controls	NULL
.	NULL

Quantification	NULL
was	NULL
performed	NULL
using	NULL
a	NULL
GS-363	NULL
molecular	NULL
imager	NULL
(	NULL
Bio-Rad	NULL
)	NULL
,	NULL
and	NULL
blots	NULL
were	NULL
then	NULL
submitted	NULL
to	NULL
autoradiography	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

radioactivity	NULL
quantification	NULL
(	NULL
see	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
``	NULL
)	NULL
indicates	NULL
that	NULL
the	NULL
GATA-1	NULL
signal	NULL
,	NULL
which	NULL
was	NULL
minimal	NULL
in	NULL
control	NULL
cells	NULL
,	NULL
is	NULL
3-fold	NULL
less	NULL
important	NULL
in	NULL
DOX-treated	NULL
cells	NULL
.	NULL

Thus	NULL
,	NULL
DOX-induced	NULL
differentiation	NULL
of	NULL
K562	NULL
cells	NULL
did	NULL
not	NULL
result	NULL
from	NULL
an	NULL
enhancement	NULL
of	NULL
erythroid	NULL
gene	NULL
transcription	NULL
,	NULL
despite	NULL
an	NULL
increased	NULL
steady-state	NULL
level	NULL
of	NULL
PBGD	NULL
and	NULL
y-globin	NULL
mRNAs	NULL
.	NULL

Hybridization	NULL
of	NULL
radiolabeled	NULL
RNA	NULL
with	NULL
a	NULL
GAPDH	NULL
cDNA	NULL
probe	NULL
indicated	NULL
that	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
treated	NULL
and	NULL
untreated	NULL
nuclei	NULL
was	NULL
nearly	NULL
the	NULL
same	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Increased	NULL
Stability	NULL
of	NULL
Erythroid	NULL
mRNAs	NULL
in	NULL
DOX-	NULL
but	NULL
not	NULL
ACLA-treated	NULL
Cells	NULL
.	NULL

Because	NULL
transcriptional	NULL
activation	NULL
of	NULL
PBGD	NULL
and	NULL
y-globin	NULL
genes	NULL
was	NULL
not	NULL
involved	NULL
in	NULL
DOX-treated	NULL
cells	NULL
,	NULL
the	NULL
accumulation	NULL
of	NULL
these	NULL
mRNAs	NULL
may	NULL
be	NULL
the	NULL
result	NULL
of	NULL
their	NULL
stabilization	NULL
.	NULL

Furthermore	NULL
,	NULL
although	NULL
ACLA	NULL
stimulated	NULL
erythroid	NULL
gene	NULL
transcription	NULL
,	NULL
the	NULL
involvement	NULL
of	NULL
a	NULL
posttranscriptional	NULL
event	NULL
could	NULL
not	NULL
be	NULL
excluded	NULL
.	NULL

To	NULL
assess	NULL
this	NULL
possibility	NULL
,	NULL
the	NULL
half-lives	NULL
of	NULL
PBGD	NULL
and	NULL
GATA-1	NULL
mRNAs	NULL
were	NULL
determined	NULL
by	NULL
using	NULL
the	NULL
RNA	NULL
synthesis	NULL
inhibitor	NULL
actinomycin	NULL
D	NULL
(	NULL
5	NULL
ug/m	NULL
!	NULL
)	NULL

added	NULL
to	NULL
either	NULL
uninduced	NULL
or	NULL
induced	NULL
K562	NULL
cells	NULL
.	NULL

Preliminary	NULL
experiments	NULL
showed	NULL
that	NULL
actinomycin	NULL
D	NULL
,	NULL
up	NULL
to	NULL
10	NULL
ug/ml	NULL
,	NULL
was	NULL
without	NULL
any	NULL
effect	NULL
on	NULL
viability	NULL
and	NULL
differentiation	NULL
of	NULL
K562	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

After	NULL
3	NULL
days	NULL
of	NULL
treatment	NULL
with	NULL
ACLA	NULL
or	NULL
DOX	NULL
,	NULL
the	NULL
level	NULL
of	NULL
mRNA	NULL
was	NULL
determined	NULL
by	NULL
Northern	NULL
blot	NULL
at	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
8	NULL
h	NULL
following	NULL
actinomycin	NULL
D	NULL
addition	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
the	NULL
half-life	NULL
of	NULL
PBGD	NULL
mRNA	NULL
in	NULL
uninduced	NULL
K562	NULL
cells	NULL
was	NULL
about	NULL
Cell	NULL
Growth	NULL
&	NULL
Differentiation	NULL
#	NULL
_	NULL
Control	NULL
1.5-e	NULL
ACLA	NULL
a	NULL
-	NULL
DOX	NULL
a	NULL
}	NULL
E11	NULL
)	NULL
I	NULL
J	NULL
&	NULL
3	NULL
4	NULL
€	NULL
£	NULL
<	NULL
*	NULL
\	NULL
0.0	NULL
t	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
I	NULL
0	NULL
2	NULL
4	NULL
6	NULL
8	NULL
10	NULL
hours	NULL
Control	NULL
ACLA	NULL
DOX	NULL
hours	NULL
0	NULL
2	NULL
4	NULL
8	NULL
0	NULL
2	NULL
4	NULL
8	NULL
0	NULL
2	NULL
4	NULL
8	NULL
moo	NULL
Obb	NULL
#	NULL
Over	NULL
-	NULL
...	NULL
@	NULL
0	NULL
@	NULL
Q	NULL
cope	NULL
¢000	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

-	NULL
Stability	NULL
of	NULL
PBGD	NULL
mRNA	NULL
in	NULL
ACLA-	NULL
and	NULL
DOX-treated	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
grown	NULL
for	NULL
72	NULL
h	NULL
in	NULL
medium	NULL
alone	NULL
(	NULL
Contro	NULL
!	NULL
)	NULL

or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
20	NULL
nm	NULL
ACLA	NULL
or	NULL
40	NULL
nm	NULL
DOX	NULL
.	NULL

Total	NULL
RNA	NULL
were	NULL
isolated	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
8	NULL
h	NULL
after	NULL
actinomycin	NULL
D	NULL
addition	NULL
(	NULL
5	NULL
ug/ml	NULL
!	NULL
)	NULL

and	NULL
analyzed	NULL
by	NULL
Northern	NULL
blot	NULL
with	NULL
PBGD	NULL
and	NULL
GAPDH	NULL
cDNA	NULL
probes	NULL
.	NULL

Results	NULL
from	NULL
densitometric	NULL
analysis	NULL
of	NULL
the	NULL
autoradiograms	NULL
were	NULL
normalized	NULL
to	NULL
GAPDH	NULL
mRNA	NULL
level	NULL
and	NULL
plotted	NULL
as	NULL
the	NULL
means	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Bars	NULL
,	NULL
SD	NULL
.	NULL

5.5	NULL
h	NULL
and	NULL
was	NULL
not	NULL
significantly	NULL
modified	NULL
after	NULL
3	NULL
days	NULL
of	NULL
treatment	NULL
with	NULL
20	NULL
nm	NULL
ACLA	NULL
,	NULL
despite	NULL
a	NULL
great	NULL
difference	NULL
in	NULL
hemoglobinized	NULL
cell	NULL
levels	NULL
(	NULL
72	NULL
%	NULL
in	NULL
ACLA-treated	NULL
cells	NULL
versus	NULL
2	NULL
%	NULL
in	NULL
control	NULL
cells	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
changes	NULL
in	NULL
the	NULL
steady-state	NULL
level	NULL
of	NULL
PBGD	NULL
mRNA	NULL
in	NULL
ACLA-treated	NULL
cells	NULL
were	NULL
not	NULL
a	NULL
consequence	NULL
of	NULL
altered	NULL
mRNA	NULL
stability	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
stability	NULL
of	NULL
PBGD	NULL
mRNA	NULL
gradually	NULL
increased	NULL
during	NULL
the	NULL
DOX	NULL
differentiation	NULL
time	NULL
course	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
PBGD	NULL
mRNA	NULL
half-life	NULL
in	NULL
DOX-treated	NULL
cells	NULL
was	NULL
comparable	NULL
to	NULL
that	NULL
of	NULL
control	NULL
cells	NULL
at	NULL
24	NULL
h	NULL
after	NULL
induction	NULL
and	NULL
increased	NULL
up	NULL
to	NULL
6.5	NULL
h	NULL
and	NULL
notably	NULL
greater	NULL
than	NULL
8	NULL
h	NULL
at	NULL
48	NULL
and	NULL
72	NULL
h	NULL
,	NULL
respectively	NULL
.	NULL

This	NULL
increase	NULL
in	NULL
stability	NULL
occurred	NULL
in	NULL
a	NULL
specific	NULL
manner	NULL
,	NULL
as	NULL
attested	NULL
by	NULL
the	NULL
unchanged	NULL
level	NULL
of	NULL
GAPDH	NULL
mRNA	NULL
in	NULL
DOX-treated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
GATA-1	NULL
mRNA	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
the	NULL
half-life	NULL
of	NULL
GATA-1	NULL
mRNA	NULL
was	NULL
not	NULL
affected	NULL
in	NULL
ACLA-treated	NULL
cells	NULL
,	NULL
whereas	NULL
DOX	NULL
induced	NULL
an	NULL
increase	NULL
in	NULL
GATA-1	NULL
mRNA	NULL
stability	NULL
in	NULL
comparison	NULL
with	NULL
untreated	NULL
cells	NULL
.	NULL

As	NULL
for	NULL
PBGD	NULL
mRNA	NULL
,	NULL
the	NULL
increase	NULL
in	NULL
GATA-1	NULL
mRNA	NULL
half-life	NULL
appeared	NULL
48	NULL
h	NULL
after	NULL
induction	NULL
(	NULL
6	NULL
versus	NULL
4	NULL
h	NULL
)	NULL
and	NULL
reached	NULL
a	NULL
maximum	NULL
at	NULL
72	NULL
h	NULL
(	NULL
8	NULL
versus	NULL
4	NULL
h	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
the	NULL
increase	NULL
in	NULL
the	NULL
GATA-1	NULL
transcript	NULL
half-life	NULL
in	NULL
DOX-treated	NULL
cells	NULL
was	NULL
lower	NULL
than	NULL
that	NULL
of	NULL
PBGD	NULL
mRNA	NULL
.	NULL

Besides	NULL
,	NULL
the	NULL
half-life	NULL
of	NULL
y-globin	NULL
mRNA	NULL
,	NULL
which	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
at	NULL
least	NULL
24	NULL
h	NULL
in	NULL
K562	NULL
cells	NULL
(	NULL
24	NULL
)	NULL
,	NULL
could	NULL
not	NULL
be	NULL
determined	NULL
,	NULL
because	NULL
cell	NULL
viability	NULL
in	NULL
long-term	NULL
culture	NULL
in	NULL
the	NULL
1.5-	NULL
a	NULL
CONTROL	NULL
©	NULL
-	NULL
AcLA	NULL
a	NULL
a	NULL
_	NULL
Dox	NULL
g	NULL
1.047	NULL
3	NULL
€	NULL
f	NULL
¢	NULL
~	NULL
\	NULL
0.0	NULL
T	NULL
T	NULL
'	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
U	NULL
0	NULL
2	NULL
4	NULL
6	NULL
8	NULL
10	NULL
hours	NULL
Control	NULL
ACLA	NULL
DOX	NULL
hours	NULL
0	NULL
2	NULL
4	NULL
8	NULL
0	NULL
2	NULL
4	NULL
8	NULL
0	NULL
2	NULL
4	NULL
8	NULL
can	NULL
:	NULL
0000	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

-	NULL
Stability	NULL
of	NULL
GATA-1	NULL
mRNA	NULL
in	NULL
ACLA-	NULL
and	NULL
DOX-treated	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
grown	NULL
for	NULL
72	NULL
h	NULL
in	NULL
medium	NULL
alone	NULL
(	NULL
Contro	NULL
!	NULL
)	NULL

or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
20	NULL
nm	NULL
ACLA	NULL
or	NULL
40	NULL
nm	NULL
DOX	NULL
.	NULL

Total	NULL
RNA	NULL
were	NULL
isolated	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
8	NULL
h	NULL
after	NULL
actinomycin	NULL
D	NULL
addition	NULL
(	NULL
5	NULL
ug/m	NULL
!	NULL
)	NULL

and	NULL
analyzed	NULL
by	NULL
Northern	NULL
blot	NULL
with	NULL
GATA-1	NULL
and	NULL
GAPDH	NULL
cDNA	NULL
probes	NULL
.	NULL

Results	NULL
from	NULL
densitometric	NULL
analysis	NULL
of	NULL
the	NULL
autoradiograms	NULL
were	NULL
normalized	NULL
to	NULL
GAPDH	NULL
mRNA	NULL
level	NULL
and	NULL
plotted	NULL
as	NULL
the	NULL
means	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Bars	NULL
,	NULL
SD	NULL
.	NULL

presence	NULL
of	NULL
actinomycin	NULL
D	NULL
(	NULL
about	NULL
12	NULL
h	NULL
)	NULL
was	NULL
markedly	NULL
affected	NULL
(	NULL
20	NULL
%	NULL
of	NULL
dead	NULL
cells	NULL
)	NULL
.	NULL

Requirement	NULL
of	NULL
de	NULL
Novo	NULL
Protein	NULL
Synthesis	NULL
in	NULL
Anthracycline-induced	NULL
Differentiation	NULL
.	NULL

The	NULL
transcriptional	NULL
activation	NULL
of	NULL
erythroid	NULL
genes	NULL
induced	NULL
by	NULL
ACLA	NULL
suggests	NULL
the	NULL
involvement	NULL
of	NULL
transcription	NULL
factors	NULL
and	NULL
possibly	NULL
their	NULL
de	NULL
novo	NULL
synthesis	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
posttranscriptional	NULL
stabilization	NULL
of	NULL
erythroid	NULL
mRNAs	NULL
in	NULL
DOX-treated	NULL
cells	NULL
may	NULL
also	NULL
require	NULL
protein	NULL
synthesis	NULL
.	NULL

To	NULL
assess	NULL
this	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
requirement	NULL
,	NULL
K562	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
48	NULL
h	NULL
with	NULL
ACLA	NULL
or	NULL
DOX	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
protein	NULL
synthesis	NULL
inhibitor	NULL
CHX	NULL
.	NULL

Preliminary	NULL
experiments	NULL
showed	NULL
that	NULL
5	NULL
ug/ml	NULL
CHX	NULL
efficiently	NULL
blocked	NULL
total	NULL
protein	NULL
synthesis	NULL
by	NULL
at	NULL
least	NULL
95	NULL
%	NULL
,	NULL
without	NULL
affecting	NULL
the	NULL
cell	NULL
viability	NULL
of	NULL
cultures	NULL
treated	NULL
with	NULL
CHX	NULL
alone	NULL
,	NULL
CHX	NULL
and	NULL
anthracyclines	NULL
,	NULL
or	NULL
anthracyclines	NULL
alone	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Besides	NULL
,	NULL
CHX	NULL
was	NULL
seen	NULL
to	NULL
inhibit	NULL
the	NULL
appearance	NULL
of	NULL
hemoglobinized	NULL
cells	NULL
following	NULL
ACLA	NULL
or	NULL
DOX	NULL
treatment	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
which	NULL
was	NULL
supported	NULL
at	NULL
the	NULL
molecular	NULL
level	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
of	NULL
erythroid	NULL
mRNAs	NULL
.	NULL

Indeed	NULL
,	NULL
in	NULL
uninduced	NULL
cells	NULL
,	NULL
PBGD	NULL
and	NULL
y-globin	NULL
mRNA	NULL
levels	NULL
were	NULL
unchanged	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CHX	NULL
,	NULL
whereas	NULL
in	NULL
ACLA-	NULL
and	NULL
DOX-treated	NULL
cells	NULL
,	NULL
CHX	NULL
abolished	NULL
the	NULL
overexpression	NULL
of	NULL
PBGD	NULL
and	NULL
y-globin	NULL
mRNAs	NULL
,	NULL
thus	NULL
leading	NULL
back	NULL
to	NULL
mRNA	NULL
basal	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
in	NULL
ACLA-treated	NULL
cells	NULL
,	NULL
the	NULL
increase	NULL
in	NULL
GATA-1	NULL
and	NULL
NF-E2	NULL
mRNA	NULL
levels	NULL
was	NULL
abolished	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CHX	NULL
(	NULL
Fig	NULL
.	NULL

48	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
NF-E2	NULL
mRNA	NULL
in	NULL
control	NULL
and	NULL
DOX-treated	NULL
cells	NULL
was	NULL
only	NULL
slightly	NULL
affected	NULL
by	NULL
CHX	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
,	NULL
whereas	NULL
that	NULL
of	NULL
1025	NULL
1026	NULL
-	NULL
Regulation	NULL
of	NULL
Erythroid	NULL
Gene	NULL
Expression	NULL
by	NULL
Anthracyclines	NULL
Table	NULL
1	NULL
|	NULL
Inhibition	NULL
of	NULL
anthracycline-induced	NULL
differentiation	NULL
of	NULL
K562	NULL
cells	NULL
by	NULL
CHX	NULL
Hemoglobinized	NULL
cells	NULL
(	NULL
%	NULL
)	NULL
``	NULL
Inducer	NULL
Without	NULL
CHX	NULL
With	NULL
CHX	NULL
None	NULL
3.0	NULL
+	NULL
0.5	NULL
3.5	NULL
+	NULL
0.5	NULL
ACLA	NULL
53.0	NULL
+	NULL
2.0	NULL
8.0	NULL
+	NULL
0.6	NULL
DOX	NULL
46.0	NULL
+	NULL
1.0	NULL
6.0	NULL
+	NULL
0.4	NULL
*	NULL
Differentiation	NULL
of	NULL
K562	NULL
cells	NULL
was	NULL
determined	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
benzidine-positive	NULL
cells	NULL
after	NULL
2	NULL
days	NULL
of	NULL
culture	NULL
with	NULL
the	NULL
indicated	NULL
inducer	NULL
and	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
5	NULL
ug/ml	NULL
CHX	NULL
.	NULL

Results	NULL
are	NULL
the	NULL
mean	NULL
*	NULL
SD	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

GATA-1	NULL
mRNA	NULL
was	NULL
decreased	NULL
under	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
control	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
despite	NULL
the	NULL
distinct	NULL
modes	NULL
of	NULL
action	NULL
of	NULL
ACLA	NULL
and	NULL
DOX	NULL
,	NULL
they	NULL
both	NULL
require	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
to	NULL
achieve	NULL
overexpression	NULL
of	NULL
erythroid	NULL
genes	NULL
and	NULL
differentiation	NULL
of	NULL
K562	NULL
cells	NULL
.	NULL

Increase	NULL
in	NULL
GATA-1	NULL
Protein	NULL
Level	NULL
in	NULL
ACLA-	NULL
but	NULL
not	NULL
DOX-treated	NULL
Cells	NULL
.	NULL

To	NULL
verify	NULL
that	NULL
enhancement	NULL
of	NULL
GATA-1	NULL
gene	NULL
expression	NULL
in	NULL
ACLA-treated	NULL
cells	NULL
resulted	NULL
in	NULL
an	NULL
increased	NULL
protein	NULL
level	NULL
,	NULL
immunoblots	NULL
were	NULL
performed	NULL
by	NULL
using	NULL
a	NULL
monoclonal	NULL
antibody	NULL
directed	NULL
against	NULL
GATA-1	NULL
.	NULL

This	NULL
antibody	NULL
appeared	NULL
to	NULL
recognize	NULL
a	NULL
single	NULL
band	NULL
with	NULL
an	NULL
apparent	NULL
M	NULL
,	NULL
of	NULL
50,000	NULL
in	NULL
K562	NULL
cell	NULL
extracts	NULL
,	NULL
which	NULL
corresponds	NULL
to	NULL
the	NULL
purified	NULL
recombinant	NULL
GATA-1	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

GATA-1	NULL
protein	NULL
level	NULL
was	NULL
studied	NULL
as	NULL
a	NULL
function	NULL
of	NULL
time	NULL
after	NULL
ACLA	NULL
treatment	NULL
of	NULL
K562	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
a	NULL
marked	NULL
increase	NULL
in	NULL
GATA-1	NULL
protein	NULL
appeared	NULL
as	NULL
soon	NULL
as	NULL
24	NULL
h	NULL
after	NULL
treatment	NULL
,	NULL
in	NULL
comparison	NULL
with	NULL
control	NULL
cells	NULL
,	NULL
and	NULL
was	NULL
sustained	NULL
up	NULL
to	NULL
72	NULL
h.	NULL
in	NULL
contrast	NULL
,	NULL
DOX	NULL
failed	NULL
to	NULL
increase	NULL
GATA-1	NULL
protein	NULL
level	NULL
,	NULL
as	NULL
expected	NULL
from	NULL
the	NULL
unchanged	NULL
mRNA	NULL
level	NULL
(	NULL
Fig	NULL
.	NULL

48	NULL
;	NULL
Ref	NULL
.	NULL

13	NULL
)	NULL
and	NULL
despite	NULL
the	NULL
stabilization	NULL
of	NULL
GATA-1	NULL
mRNA	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Discussion	NULL
In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
used	NULL
human	NULL
multipotent	NULL
K562	NULL
cells	NULL
as	NULL
a	NULL
model	NULL
!	NULL

system	NULL
to	NULL
examine	NULL
the	NULL
molecular	NULL
aspects	NULL
of	NULL
erythroid	NULL
differentiation	NULL
induced	NULL
by	NULL
conventional	NULL
cancer	NULL
chemothera-peutic	NULL
agents	NULL
.	NULL

Among	NULL
the	NULL
potent	NULL
antitumor	NULL
drugs	NULL
of	NULL
the	NULL
anthracycline	NULL
group	NULL
,	NULL
ACLA	NULL
and	NULL
DOX	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
specifically	NULL
stimulate	NULL
hemoglobin	NULL
synthesis	NULL
and	NULL
expression	NULL
of	NULL
erythroid	NULL
genes	NULL
such	NULL
as	NULL
y-globin	NULL
and	NULL
PBGD	NULL
(	NULL
13	NULL
)	NULL
.	NULL

The	NULL
present	NULL
data	NULL
clearly	NULL
indicate	NULL
that	NULL
these	NULL
two	NULL
anthracyclines	NULL
affect	NULL
the	NULL
erythroid	NULL
gene	NULL
program	NULL
through	NULL
distinct	NULL
molecular	NULL
mechanisms	NULL
.	NULL

They	NULL
reinforce	NULL
the	NULL
differences	NULL
previously	NULL
described	NULL
for	NULL
cellular	NULL
and	NULL
biochemical	NULL
events	NULL
associated	NULL
with	NULL
ACLA-	NULL
and	NULL
DOX-differentiating	NULL
effects	NULL
:	NULL
these	NULL
include	NULL
distinct	NULL
effects	NULL
on	NULL
the	NULL
synthesis	NULL
of	NULL
nonglobin	NULL
proteins	NULL
,	NULL
on	NULL
the	NULL
hemoglobin	NULL
types	NULL
produced	NULL
(	NULL
11	NULL
,	NULL
13	NULL
)	NULL
,	NULL
and	NULL
on	NULL
the	NULL
appearance	NULL
of	NULL
membrane	NULL
EPOR	NULL
(	NULL
12	NULL
)	NULL
,	NULL
known	NULL
to	NULL
play	NULL
a	NULL
key	NULL
role	NULL
in	NULL
the	NULL
differentiation	NULL
of	NULL
erythroid	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
the	NULL
differentiating	NULL
effects	NULL
of	NULL
both	NULL
drugs	NULL
were	NULL
irreversible	NULL
and	NULL
were	NULL
associated	NULL
with	NULL
a	NULL
loss	NULL
of	NULL
self-renewal	NULL
capacity	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Such	NULL
observations	NULL
were	NULL
consistent	NULL
with	NULL
a	NULL
process	NULL
of	NULL
terminal	NULL
differentiation	NULL
.	NULL

Using	NULL
run-on	NULL
assays	NULL
,	NULL
ACLA	NULL
was	NULL
seen	NULL
to	NULL
induce	NULL
an	NULL
increased	NULL
transcription	NULL
of	NULL
late	NULL
erythroid-specific	NULL
genes	NULL
,	NULL
including	NULL
y-globin	NULL
,	NULL
PBGD	NULL
,	NULL
and	NULL
EPOR	NULL
,	NULL
without	NULL
any	NULL
effect	NULL
on	NULL
their	NULL
A	NULL
Control	NULL
_	NULL
ACLA	NULL
DOX	NULL
CHK	NULL
|	NULL
O-	NULL
+	NULL
O-	NULL
0	NULL
+	NULL
-	NULL
+	NULL
y-globin	NULL
.	NULL

.	NULL

.	NULL

u	NULL
.	NULL

lke	NULL
Control	NULL
_	NULL
ACLA	NULL
DOX	NULL
CHX	NULL
eo	NULL
F	NULL
<	NULL
o	NULL
ot	NULL
o-	NULL
oo+	NULL
GATA-1	NULL
...	NULL
U	NULL
0	NULL
<	NULL
Ki	NULL
#	NULL
#	NULL
-	NULL
»	NULL
»	NULL
GAPDH	NULL
...	NULL
..	NULL
C	NULL
T	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

-	NULL
Effect	NULL
of	NULL
CHX	NULL
on	NULL
ACLA-	NULL
and	NULL
DOX-induced	NULL
mRNA	NULL
increase	NULL
.	NULL

Cells	NULL
were	NULL
grown	NULL
for	NULL
48	NULL
h	NULL
in	NULL
medium	NULL
alone	NULL
(	NULL
Contro	NULL
!	NULL
)	NULL

or	NULL
with	NULL
20	NULL
nm	NULL
ACLA	NULL
or	NULL
40	NULL
nm	NULL
DOX	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
+	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
of	NULL
CHX	NULL
(	NULL
5	NULL
ug/m	NULL
!	NULL
)	NULL

.	NULL

Northern	NULL
blots	NULL
of	NULL
total	NULL
RNAs	NULL
were	NULL
successively	NULL
hybridized	NULL
with	NULL
PBGD	NULL
and	NULL
y-globin	NULL
(	NULL
A	NULL
)	NULL
and	NULL
GATA-1	NULL
and	NULL
NF-E2	NULL
(	NULL
B	NULL
)	NULL
probes	NULL
.	NULL

Each	NULL
membrane	NULL
was	NULL
then	NULL
hybridized	NULL
with	NULL
a	NULL
GAPDH	NULL
probe	NULL
as	NULL
control	NULL
.	NULL

The	NULL
results	NULL
presented	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

mRNA	NULL
stability	NULL
.	NULL

This	NULL
enhanced	NULL
transcription	NULL
could	NULL
explain	NULL
the	NULL
previously	NULL
observed	NULL
accumulation	NULL
of	NULL
the	NULL
corresponding	NULL
erythroid	NULL
mRNAs	NULL
(	NULL
13	NULL
)	NULL
and	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
erythroid	NULL
regulatory	NULL
regions	NULL
of	NULL
these	NULL
genes	NULL
(	NULL
26	NULL
)	NULL
during	NULL
the	NULL
ACLA	NULL
differentiation	NULL
time	NULL
course	NULL
.	NULL

Furthermore	NULL
,	NULL
this	NULL
mRNA	NULL
increase	NULL
was	NULL
inhibited	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CHX	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
enhancement	NULL
of	NULL
the	NULL
transcription	NULL
rate	NULL
was	NULL
dependent	NULL
on	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
.	NULL

As	NULL
reported	NULL
previously	NULL
,	NULL
using	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
and	NULL
Northern	NULL
blotting	NULL
,	NULL
the	NULL
differentiating	NULL
effect	NULL
of	NULL
ACLA	NULL
was	NULL
also	NULL
seen	NULL
to	NULL
be	NULL
accompanied	NULL
by	NULL
an	NULL
overexpression	NULL
of	NULL
the	NULL
erythroid	NULL
transcription	NULL
factors	NULL
GATA-1	NULL
and	NULL
NF-E2	NULL
(	NULL
13	NULL
,	NULL
23	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
butyrate	NULL
(	NULL
27	NULL
)	NULL
,	NULL
Cell	NULL
Growth	NULL
&	NULL
Differentiation	NULL
G	NULL
_C	NULL
ACLA	NULL
DOX	NULL
24h	NULL
48h	NULL
72h	NULL
24h	NULL
48h	NULL
72h	NULL
kDa	NULL
66.2	NULL
57.5	NULL
-e-	NULL
o	NULL
#	NULL
u	NULL
»	NULL
ap	NULL
ap	NULL
=-	NULL
@	NULL
o	NULL
40.0	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

-	NULL
Analysis	NULL
of	NULL
GATA-1	NULL
protein	NULL
level	NULL
in	NULL
ACLA-	NULL
and	NULL
DOX-treated	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
grown	NULL
in	NULL
medium	NULL
alone	NULL
(	NULL
Lane	NULL
C	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
20	NULL
nm	NULL
ACLA	NULL
or	NULL
40	NULL
nm	NULL
DOX	NULL
for	NULL
24	NULL
,	NULL
48	NULL
,	NULL
or	NULL
72	NULL
h.	NULL
After	NULL
cell	NULL
lysis	NULL
,	NULL
60	NULL
ug	NULL
total	NULL
proteins	NULL
were	NULL
separated	NULL
by	NULL
denaturating	NULL
electrophoresis	NULL
,	NULL
and	NULL
then	NULL
immunoblot-ting	NULL
was	NULL
performed	NULL
using	NULL
a	NULL
monoclonal	NULL
antibody	NULL
directed	NULL
against	NULL
human	NULL
GATA-1	NULL
.	NULL

Purified	NULL
recombinant	NULL
human	NULL
GATA-1	NULL
protein	NULL
was	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
(	NULL
Lane	NULL
G	NULL
)	NULL
.	NULL

suggesting	NULL
that	NULL
such	NULL
erythroid	NULL
K562	NULL
inducers	NULL
may	NULL
exert	NULL
their	NULL
differentiating	NULL
effects	NULL
in	NULL
part	NULL
by	NULL
up-regulating	NULL
the	NULL
expression	NULL
of	NULL
key	NULL
erythroid	NULL
transcription	NULL
factors	NULL
.	NULL

The	NULL
present	NULL
data	NULL
strongly	NULL
argue	NULL
in	NULL
favor	NULL
of	NULL
this	NULL
hypothesis	NULL
.	NULL

First	NULL
,	NULL
the	NULL
transcription	NULL
rate	NULL
of	NULL
GATA-1	NULL
was	NULL
enhanced	NULL
during	NULL
ACLA	NULL
treatment	NULL
without	NULL
any	NULL
modification	NULL
of	NULL
its	NULL
mRNA	NULL
stability	NULL
,	NULL
and	NULL
similar	NULL
to	NULL
late	NULL
erythroid	NULL
genes	NULL
,	NULL
this	NULL
up-regulation	NULL
appeared	NULL
to	NULL
be	NULL
dependent	NULL
on	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
.	NULL

Second	NULL
,	NULL
GATA-1	NULL
protein	NULL
content	NULL
increased	NULL
during	NULL
cell	NULL
maturation	NULL
,	NULL
as	NULL
analyzed	NULL
by	NULL
Western	NULL
blotting	NULL
.	NULL

Nevertheless	NULL
,	NULL
the	NULL
involvement	NULL
of	NULL
other	NULL
erythroid-specific	NULL
or	NULL
ubiquitous	NULL
transcription	NULL
factors	NULL
in	NULL
ACLA-induced	NULL
differentiation	NULL
of	NULL
K562	NULL
cells	NULL
could	NULL
not	NULL
be	NULL
ruled	NULL
out	NULL
.	NULL

Indeed	NULL
,	NULL
Krlip-pel	NULL
family	NULL
factors	NULL
such	NULL
as	NULL
the	NULL
ubiquitous	NULL
protein	NULL
Sp1	NULL
and	NULL
the	NULL
erythroid-restricted	NULL
factor	NULL
EKLF	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
physically	NULL
interact	NULL
and	NULL
functionally	NULL
synergize	NULL
with	NULL
GATA-1	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Cooperative	NULL
interactions	NULL
between	NULL
GATA	NULL
proteins	NULL
and	NULL
NF-E2	NULL
or	NULL
AP-1	NULL
transcription	NULL
factors	NULL
(	NULL
f.e	NULL
.	NULL

,	NULL
Jun	NULL
and	NULL
Fos	NULL
)	NULL
have	NULL
also	NULL
been	NULL
described	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
endothelin	NULL
1	NULL
gene	NULL
(	NULL
29	NULL
)	NULL
and	NULL
the	NULL
e-globin	NULL
gene	NULL
(	NULL
30	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
recently	NULL
showed	NULL
that	NULL
ACLA	NULL
activated	NULL
the	NULL
GATA-1	NULL
promoter	NULL
via	NULL
a	NULL
GATA-1-independent	NULL
mechanism	NULL
,	NULL
because	NULL
this	NULL
region	NULL
does	NULL
not	NULL
contain	NULL
any	NULL
binding	NULL
site	NULL
for	NULL
this	NULL
transcription	NULL
factor	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
suggest	NULL
the	NULL
existence	NULL
of	NULL
complex	NULL
interactions	NULL
between	NULL
nonerythroid	NULL
and	NULL
erythroid-restricted	NULL
transcription	NULL
factors	NULL
,	NULL
providing	NULL
an	NULL
additional	NULL
level	NULL
of	NULL
regulation	NULL
that	NULL
could	NULL
be	NULL
affected	NULL
by	NULL
anthracycline	NULL
treatment	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
ACLA	NULL
,	NULL
the	NULL
transcription	NULL
rate	NULL
of	NULL
the	NULL
PBGD	NULL
gene	NULL
was	NULL
unchanged	NULL
in	NULL
DOX-treated	NULL
cells	NULL
.	NULL

That	NULL
of	NULL
GATA-1	NULL
appeared	NULL
as	NULL
very	NULL
weakly	NULL
expressed	NULL
in	NULL
uninduced	NULL
cells	NULL
and	NULL
even	NULL
decreased	NULL
in	NULL
DOX-treated	NULL
cells	NULL
.	NULL

Additionally	NULL
,	NULL
PBGD	NULL
and	NULL
GATA-1	NULL
mRNA	NULL
stability	NULL
was	NULL
markedly	NULL
increased	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
actinomycin	NULL
D	NULL
blockage	NULL
of	NULL
RNA	NULL
polymerase	NULL
.	NULL

The	NULL
apparent	NULL
half-lives	NULL
of	NULL
PBGD	NULL
and	NULL
GATA-1	NULL
mRNAs	NULL
were	NULL
found	NULL
to	NULL
be	NULL
notably	NULL
greater	NULL
and	NULL
slightly	NULL
greater	NULL
than	NULL
8	NULL
h	NULL
,	NULL
respectively	NULL
,	NULL
in	NULL
DOX-treated	NULL
cells	NULL
,	NULL
compared	NULL
with	NULL
4.5	NULL
and	NULL
4	NULL
h	NULL
in	NULL
uninduced	NULL
and	NULL
ACLA-treated	NULL
cells	NULL
,	NULL
respectively	NULL
.	NULL

We	NULL
chose	NULL
to	NULL
analyze	NULL
the	NULL
stability	NULL
of	NULL
these	NULL
RNAs	NULL
rather	NULL
than	NULL
that	NULL
of	NULL
globin	NULL
mRNAs	NULL
,	NULL
which	NULL
are	NULL
quite	NULL
stable	NULL
in	NULL
K562	NULL
cells	NULL
,	NULL
with	NULL
a	NULL
half-life	NULL
of	NULL
at	NULL
least	NULL
24	NULL
h	NULL
(	NULL
24	NULL
)	NULL
.	NULL

With	NULL
such	NULL
stable	NULL
mRNAs	NULL
,	NULL
the	NULL
concomitant	NULL
exposure	NULL
of	NULL
cells	NULL
for	NULL
more	NULL
than	NULL
24	NULL
h	NULL
to	NULL
both	NULL
actinomycin	NULL
D	NULL
and	NULL
antitumor	NULL
drugs	NULL
considerably	NULL
affected	NULL
cell	NULL
viability	NULL
.	NULL

The	NULL
mechanisms	NULL
by	NULL
which	NULL
DOX	NULL
could	NULL
induce	NULL
mRNA	NULL
stabilization	NULL
are	NULL
still	NULL
largely	NULL
unknown	NULL
.	NULL

The	NULL
proteins	NULL
involved	NULL
may	NULL
be	NULL
any	NULL
of	NULL
the	NULL
RNA-binding	NULL
protein	NULL
family	NULL
(	NULL
for	NULL
review	NULL
,	NULL
see	NULL
Ref	NULL
.	NULL

31	NULL
)	NULL
.	NULL

Among	NULL
them	NULL
,	NULL
polyadenylic	NULL
acid-binding	NULL
proteins	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
B-globin	NULL
mRNA	NULL
and	NULL
then	NULL
protect	NULL
mRNA	NULL
from	NULL
rapid	NULL
degradation	NULL
(	NULL
31	NULL
)	NULL
.	NULL

DOX-induced	NULL
increases	NULL
of	NULL
PBGD	NULL
and	NULL
y-globin	NULL
mRNAs	NULL
were	NULL
inhibited	NULL
by	NULL
CHX	NULL
,	NULL
indicating	NULL
that	NULL
mRNA	NULL
stabilization	NULL
was	NULL
dependent	NULL
on	NULL
de	NULL
novo	NULL
synthesis	NULL
of	NULL
proteins	NULL
,	NULL
which	NULL
could	NULL
be	NULL
a	NULL
mRNA	NULL
stability	NULL
factor	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Although	NULL
DOX	NULL
induced	NULL
the	NULL
stabilization	NULL
of	NULL
the	NULL
erythroid	NULL
transcripts	NULL
,	NULL
it	NULL
failed	NULL
to	NULL
increase	NULL
GATA-1	NULL
protein	NULL
,	NULL
which	NULL
is	NULL
in	NULL
accord	NULL
with	NULL
the	NULL
fact	NULL
that	NULL
DOX	NULL
was	NULL
found	NULL
to	NULL
alter	NULL
neither	NULL
the	NULL
binding	NULL
capacity	NULL
and	NULL
the	NULL
steady-state	NULL
mRNA	NULL
levels	NULL
of	NULL
GATA-1	NULL
or	NULL
NF-E2	NULL
(	NULL
13	NULL
)	NULL
nor	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
GATA-1	NULL
promoter	NULL
(	NULL
26	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
ACLA	NULL
,	NULL
erythroid	NULL
transcription	NULL
factor	NULL
overexpression	NULL
may	NULL
not	NULL
be	NULL
required	NULL
for	NULL
DOX-induced	NULL
erythroid	NULL
differentiation	NULL
of	NULL
K562	NULL
cells	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
reported	NULL
during	NULL
butyrate-induced	NULL
differentiation	NULL
of	NULL
erythroid	NULL
J2E	NULL
cells	NULL
in	NULL
which	NULL
GATA-1	NULL
protein	NULL
content	NULL
was	NULL
not	NULL
modified	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Besides	NULL
,	NULL
DOX-induced	NULL
stabilization	NULL
of	NULL
late	NULL
erythroid	NULL
genes	NULL
(	NULL
PBGD	NULL
)	NULL
was	NULL
accompanied	NULL
by	NULL
a	NULL
marked	NULL
rise	NULL
in	NULL
their	NULL
mRNA	NULL
and	NULL
protein	NULL
levels	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Such	NULL
a	NULL
phenomenon	NULL
could	NULL
be	NULL
sufficient	NULL
to	NULL
switch	NULL
on	NULL
the	NULL
erythroid	NULL
program	NULL
.	NULL

To	NULL
our	NULL
knowledge	NULL
,	NULL
very	NULL
few	NULL
inducing	NULL
agents	NULL
have	NULL
been	NULL
described	NULL
to	NULL
act	NULL
via	NULL
stabilization	NULL
of	NULL
differentiation	NULL
genes	NULL
.	NULL

Indeed	NULL
,	NULL
in	NULL
MEL	NULL
cells	NULL
,	NULL
hemin	NULL
and	NULL
DMSO	NULL
were	NULL
shown	NULL
to	NULL
increase	NULL
the	NULL
stability	NULL
of	NULL
globin	NULL
and	NULL
ferrochelatase	NULL
mRNAs	NULL
,	NULL
respectively	NULL
(	NULL
34	NULL
,	NULL
35	NULL
)	NULL
.	NULL

A	NULL
destabilizing	NULL
process	NULL
has	NULL
even	NULL
been	NULL
described	NULL
in	NULL
K562	NULL
cells	NULL
during	NULL
the	NULL
switch	NULL
from	NULL
erythroid	NULL
to	NULL
megakaryocytic	NULL
gene	NULL
expression	NULL
by	NULL
phorbol	NULL
ester	NULL
,	NULL
leading	NULL
to	NULL
a	NULL
marked	NULL
decrease	NULL
in	NULL
the	NULL
half-lives	NULL
of	NULL
globin	NULL
mRNAs	NULL
(	NULL
32	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
as	NULL
observed	NULL
with	NULL
ACLA	NULL
,	NULL
numerous	NULL
differentiation	NULL
inducers	NULL
of	NULL
leukemic	NULL
cells	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
regulate	NULL
the	NULL
expression	NULL
of	NULL
differentiation-associated	NULL
genes	NULL
via	NULL
transcriptional	NULL
mechanisms	NULL
.	NULL

In	NULL
MEL	NULL
cells	NULL
,	NULL
hexamethylene	NULL
bis-acetamide	NULL
and	NULL
butyrate	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
stimulate	NULL
the	NULL
rate	NULL
of	NULL
transcription	NULL
of	NULL
globin	NULL
genes	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
K562	NULL
cells	NULL
after	NULL
hemin	NULL
and	NULL
hydroxyurea	NULL
treatment	NULL
(	NULL
37	NULL
)	NULL
or	NULL
in	NULL
J2E	NULL
cells	NULL
with	NULL
GATA-1	NULL
transcripts	NULL
stimulated	NULL
by	NULL
erythropoietin	NULL
(	NULL
33	NULL
)	NULL
.	NULL

In	NULL
human	NULL
promyelocytic	NULL
HL-60	NULL
celis	NULL
,	NULL
mycophenolic	NULL
acid	NULL
and	NULL
1a,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
were	NULL
seen	NULL
to	NULL
increase	NULL
transcription	NULL
rates	NULL
of	NULL
MRP38	NULL
and	NULL
MRP14	NULL
genes	NULL
,	NULL
which	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
monomyelocytic	NULL
differentiation	NULL
of	NULL
these	NULL
cells	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
distinct	NULL
regulatory	NULL
pathways	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
erythroid-differentiating	NULL
effect	NULL
of	NULL
the	NULL
anthracycline	NULL
antitumor	NULL
drugs	NULL
ACLA	NULL
and	NULL
DOX	NULL
.	NULL

They	NULL
also	NULL
allowed	NULL
us	NULL
to	NULL
determine	NULL
the	NULL
share	NULL
of	NULL
transcriptional	NULL
and	NULL
posttranscriptional	NULL
mechanisms	NULL
in	NULL
this	NULL
effect	NULL
.	NULL

Indeed	NULL
,	NULL
ACLA	NULL
could	NULL
activate	NULL
the	NULL
transcription	NULL
of	NULL
erythroid	NULL
genes	NULL
through	NULL
overexpression	NULL
of	NULL
specific	NULL
transcription	NULL
factors	NULL
,	NULL
whereas	NULL
DOX	NULL
might	NULL
act	NULL
at	NULL
the	NULL
posttranscriptional	NULL
level	NULL
by	NULL
increasing	NULL
the	NULL
half-lives	NULL
of	NULL
mRNAs	NULL
independently	NULL
from	NULL
erythroid	NULL
transcription	NULL
factor	NULL
expression	NULL
.	NULL

The	NULL
precise	NULL
molecular	NULL
mechanisms	NULL
involved	NULL
either	NULL
in	NULL
ACLA-induced	NULL
up-regulation	NULL
of	NULL
tran	NULL
1027	NULL
1028	NULL
Regulation	NULL
of	NULL
Erythroid	NULL
Gene	NULL
Expression	NULL
by	NULL
Anthracyclines	NULL
scription	NULL
factors	NULL
or	NULL
in	NULL
DOX	NULL
stabilization	NULL
of	NULL
mRNAs	NULL
remain	NULL
to	NULL
be	NULL
defined	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Cell	NULL
Cultures	NULL
.	NULL

K562	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
FCS	NULL
and	NULL
2	NULL
mm	NULL
L-glutamine	NULL
in	NULL
a	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
humidified	NULL
atmosphere	NULL
.	NULL

Erythroid	NULL
differentiation	NULL
was	NULL
induced	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
20	NULL
nm	NULL
ACLA	NULL
(	NULL
Roger	NULL
Bellon	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
)	NULL
or	NULL
40	NULL
nm	NULL
DOX	NULL
(	NULL
Farmitalia	NULL
Carlo	NULL
Erba	NULL
,	NULL
Milan	NULL
,	NULL
Italy	NULL
)	NULL
.	NULL

Both	NULL
drugs	NULL
were	NULL
reconstituted	NULL
in	NULL
sterile	NULL
water	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
and	NULL
were	NULL
diluted	NULL
in	NULL
culture	NULL
medium	NULL
immediately	NULL
before	NULL
use	NULL
.	NULL

Nuclear	NULL
Run-on	NULL
Analysis	NULL
.	NULL

Nuclear	NULL
run-on	NULL
experiments	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
by	NULL
Morle	NULL
et	NULL
al	NULL
.	NULL

(	NULL
39	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
nuclei	NULL
were	NULL
isolated	NULL
from	NULL
5	NULL
X	NULL
10	NULL
``	NULL
K562	NULL
cells	NULL
by	NULL
lysis	NULL
in	NULL
0.5	NULL
%	NULL
NP4O	NULL
buffer	NULL
[	NULL
10	NULL
mm	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
,	NULL
60	NULL
mu	NULL
KCI	NULL
,	NULL
15	NULL
mu	NULL
NaCl	NULL
,	NULL
0.15	NULL
mm	NULL
spermidine	NULL
,	NULL
0.5	NULL
mm	NULL
spermine	NULL
,	NULL
2	NULL
mm	NULL
EDTA	NULL
,	NULL
and	NULL
0.5	NULL
%	NULL
NP4O	NULL
]	NULL
for	NULL
5	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

Nuclei	NULL
were	NULL
collected	NULL
after	NULL
centrifugation	NULL
at	NULL
700	NULL
x	NULL
g	NULL
for	NULL
5	NULL
min	NULL
at	NULL
4°C	NULL
,	NULL
resuspended	NULL
in	NULL
200	NULL
pl	NULL
nuclear	NULL
freezing	NULL
buffer	NULL
[	NULL
50	NULL
mm	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
8	NULL
)	NULL
,	NULL
75	NULL
mm	NULL
NaCl	NULL
,	NULL
0.1	NULL
mm	NULL
EDTA	NULL
,	NULL
and	NULL
50	NULL
%	NULL
glycerol	NULL
]	NULL
,	NULL
and	NULL
then	NULL
stored	NULL
at	NULL
-80°C	NULL
until	NULL
use	NULL
.	NULL

/n	NULL
vitro	NULL
RNA	NULL
elongation	NULL
was	NULL
performed	NULL
using	NULL
100	NULL
wi	NULL
nuclei	NULL
suspension	NULL
diluted	NULL
in	NULL
100	NULL
pil	NULL
transcription	NULL
buffer	NULL
[	NULL
10	NULL
mm	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
8	NULL
)	NULL
,	NULL
10	NULL
mm	NULL
MgClz	NULL
,	NULL
10	NULL
mm	NULL
MnCl	NULL
,	NULL
300	NULL
mm	NULL
KCI	NULL
,	NULL
0.5	NULL
mm	NULL
DTT	NULL
,	NULL
and	NULL
1	NULL
mm	NULL
each	NULL
ATP	NULL
,	NULL
GTP	NULL
,	NULL
and	NULL
CTP	NULL
]	NULL
and	NULL
incubated	NULL
at	NULL
30°C	NULL
for	NULL
20	NULL
min	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
100	NULL
Ci	NULL
[	NULL
a-°°PJUTP	NULL
(	NULL
3000	NULL
Ci/mmol	NULL
;	NULL
DuPont	NULL
New	NULL
England	NULL
Nuclear	NULL
)	NULL
.	NULL

Incubation	NULL
was	NULL
then	NULL
allowed	NULL
to	NULL
continue	NULL
for	NULL
5	NULL
min	NULL
at	NULL
30°C	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
0.5	NULL
ug/ul	NULL
tRNA	NULL
and	NULL
0.1	NULL
ug/ul	NULL
RNase-free	NULL
DNase	NULL
|	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
,	NULL
followed	NULL
by	NULL
proteinase	NULL
K	NULL
treatment	NULL
(	NULL
0.1	NULL
ug/ul	NULL
)	NULL
for	NULL
1	NULL
h.	NULL
Labeled	NULL
elongated	NULL
transcripts	NULL
were	NULL
isolated	NULL
with	NULL
phenol-chloroform	NULL
and	NULL
precipitated	NULL
with	NULL
ethanol	NULL
and	NULL
2.5	NULL
m	NULL
ammo-nium	NULL
acetate	NULL
.	NULL

Human	NULL
cDNAs	NULL
encoding	NULL
PBGD	NULL
,	NULL
EPOR	NULL
,	NULL
and	NULL
GATA-1	NULL
were	NULL
contained	NULL
in	NULL
pGEMT7	NULL
(	NULL
Promega	NULL
)	NULL
,	NULL
whereas	NULL
human	NULL
genomic	NULL
y-globin	NULL
DNA	NULL
and	NULL
rat	NULL
GAPDH	NULL
cDNA	NULL
were	NULL
in	NULL
Bluescript	NULL
vector	NULL
(	NULL
Stratagene	NULL
)	NULL
.	NULL

Each	NULL
linear-ized	NULL
probe	NULL
was	NULL
immobilized	NULL
onto	NULL
a	NULL
nylon	NULL
filter	NULL
(	NULL
Positive	NULL
Membrane	NULL
;	NULL
Ap-pligene	NULL
)	NULL
and	NULL
hybridized	NULL
with	NULL
equal	NULL
amounts	NULL
of	NULL
radiolabeled	NULL
RNA	NULL
.	NULL

Hybridization	NULL
for	NULL
36	NULL
h	NULL
at	NULL
42°C	NULL
was	NULL
followed	NULL
by	NULL
washing	NULL
twice	NULL
in	NULL
2x	NULL
SSC	NULL
[	NULL
1x	NULL
SSC	NULL
=	NULL
0.15	NULL
m	NULL
NaCl	NULL
and	NULL
0.015	NULL
m	NULL
Na	NULL
citrate	NULL
(	NULL
pH	NULL
7.0	NULL
)	NULL
]	NULL
and	NULL
0.1	NULL
%	NULL
SDS	NULL
at	NULL
50°C	NULL
for	NULL
10	NULL
min	NULL
and	NULL
twice	NULL
in	NULL
1	NULL
%	NULL
SSC	NULL
and	NULL
0.1	NULL
%	NULL
SDS	NULL
at	NULL
60°C	NULL
for	NULL
30	NULL
min	NULL
.	NULL

Quantification	NULL
of	NULL
radiolabeled	NULL
RNA	NULL
hybridization	NULL
was	NULL
performed	NULL
using	NULL
a	NULL
GS	NULL
363	NULL
molecular	NULL
imager	NULL
(	NULL
Bio-Rad	NULL
)	NULL
.	NULL

RNA	NULL
Analysis	NULL
.	NULL

Total	NULL
RNAs	NULL
were	NULL
extracted	NULL
using	NULL
Trizol	NULL
reagent	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
and	NULL
submitted	NULL
to	NULL
electrophoresis	NULL
and	NULL
Northem	NULL
blot	NULL
hybridization	NULL
with	NULL
radiolabeled	NULL
probes	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
13	NULL
)	NULL
.	NULL

For	NULL
the	NULL
determination	NULL
of	NULL
mRNA	NULL
stability	NULL
,	NULL
each	NULL
culture	NULL
period	NULL
(	NULL
1-3	NULL
days	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
ACLA	NULL
or	NULL
DOX	NULL
)	NULL
was	NULL
followed	NULL
by	NULL
a	NULL
treatment	NULL
with	NULL
5	NULL
g/m	NULL
!	NULL

actinomycin	NULL
D	NULL
for	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
8	NULL
h	NULL
before	NULL
RNA	NULL
extraction	NULL
.	NULL

The	NULL
Northern	NULL
blot	NULL
autoradiograms	NULL
were	NULL
quantified	NULL
by	NULL
densitometry	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
effect	NULL
of	NULL
protein	NULL
synthesis	NULL
inhibition	NULL
,	NULL
CHX	NULL
was	NULL
added	NULL
2	NULL
h	NULL
before	NULL
the	NULL
beginning	NULL
of	NULL
ACLA	NULL
or	NULL
DOX	NULL
treatment	NULL
at	NULL
the	NULL
noncytotoxic	NULL
concentration	NULL
of	NULL
5	NULL
ug/ml	NULL
.	NULL

The	NULL
mRNAs	NULL
were	NULL
extracted	NULL
after	NULL
48	NULL
h	NULL
of	NULL
culture	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
differentiation	NULL
inducers	NULL
and	NULL
analyzed	NULL
by	NULL
Northern	NULL
blot	NULL
.	NULL

As	NULL
controls	NULL
,	NULL
K562	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
20	NULL
nm	NULL
ACLA	NULL
or	NULL
40	NULL
nm	NULL
DOX	NULL
alone	NULL
or	NULL
CHX	NULL
alone	NULL
,	NULL
and	NULL
cell	NULL
viability	NULL
was	NULL
determined	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
in	NULL
each	NULL
culture	NULL
condition	NULL
.	NULL

GATA-1	NULL
Protein	NULL
Analysis	NULL
.	NULL

About	NULL
5	NULL
x	NULL
10°	NULL
cells	NULL
were	NULL
lysed	NULL
in	NULL
Laemmii	NULL
sample	NULL
buffer	NULL
and	NULL
immediately	NULL
boiled	NULL
for	NULL
5	NULL
min	NULL
.	NULL

Protein	NULL
concentration	NULL
was	NULL
determined	NULL
using	NULL
the	NULL
Bio-Rad	NULL
protein	NULL
assay	NULL
method	NULL
,	NULL
and	NULL
60	NULL
ug	NULL
protein	NULL
were	NULL
loaded	NULL
on	NULL
a	NULL
10	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
.	NULL

The	NULL
separated	NULL
proteins	NULL
were	NULL
then	NULL
transferred	NULL
onto	NULL
a	NULL
nitrocellulose	NULL
membrane	NULL
(	NULL
Hybond	NULL
C	NULL
;	NULL
Amer-sham	NULL
)	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
pretreated	NULL
for	NULL
1	NULL
h	NULL
with	NULL
5	NULL
%	NULL
dry	NULL
milk	NULL
containing	NULL
Tris-buffered	NULL
saline	NULL
and	NULL
incubated	NULL
overnight	NULL
with	NULL
anti-GATA-1	NULL
monoclonal	NULL
antibody	NULL
(	NULL
SC-265	NULL
;	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
1	NULL
ug/ml	NULL
.	NULL

After	NULL
washing	NULL
with	NULL
0.05	NULL
%	NULL
Tween	NULL
20-containing	NULL
Tris-buffered	NULL
saline	NULL
,	NULL
the	NULL
membrane	NULL
was	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
with	NULL
antirat	NULL
IgG	NULL
conjugated	NULL
with	NULL
horseradish	NULL
peroxidase	NULL
(	NULL
Amersham	NULL
)	NULL
,	NULL
and	NULL
the	NULL
immunore-active	NULL
proteins	NULL
were	NULL
visualized	NULL
using	NULL
the	NULL
enhanced	NULL
chemiluminescence	NULL
system	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

Purified	NULL
recombinant	NULL
human	NULL
GATA-1	NULL
protein	NULL
was	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
.	NULL

Acknowledgments	NULL
We	NULL
are	NULL
grateful	NULL
to	NULL
Dr.	NULL
Zina	NULL
Doubeiskoivskaia	NULL
for	NULL
her	NULL
help	NULL
in	NULL
GATA-1	NULL
protein	NULL
expression	NULL
and	NULL
purification	NULL
.	NULL

We	NULL
thank	NULL
Dr.	NULL
Sergio	NULL
Ottolenghi	NULL
for	NULL
y-globin	NULL
,	NULL
EPOR	NULL
,	NULL
and	NULL
GATA-1	NULL
probes	NULL
,	NULL
and	NULL
Drs	NULL
.	NULL

Nancy	NULL
Andrews	NULL
and	NULL
Paul-Henry	NULL
Roméo	NULL
for	NULL
NF-E2	NULL
and	NULL
PBGD	NULL
cDNAs	NULL
,	NULL
respectively	NULL
.	NULL

We	NULL
also	NULL
acknowledge	NULL
Denis	NULL
Bosson	NULL
for	NULL
his	NULL
grammatical	NULL
assistance	NULL
and	NULL
Héléne	NULL
Bobichon	NULL
for	NULL
the	NULL
photographs	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Paquette	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
and	NULL
Koeffier	NULL
,	NULL
H.	NULL
P.	NULL
Differentiation	NULL
therapy	NULL
.	NULL

Hematol	NULL
.	NULL

Oncol	NULL
.	NULL

Clin	NULL
.	NULL

N	NULL
.	NULL

Am	NULL
.	NULL

,	NULL
6	NULL
:	NULL
687-706	NULL
,	NULL
1992	NULL
.	NULL

2	NULL
.	NULL

Beere	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
and	NULL
Hickman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Differentiation	NULL
:	NULL
a	NULL
suitable	NULL
strategy	NULL
for	NULL
cancer	NULL
chemotherapy	NULL
?	NULL

Anti-Cancer	NULL
Drug	NULL
Des	NULL
.	NULL

,	NULL
8	NULL
:	NULL
299-322	NULL
,	NULL
1993	NULL
.	NULL

3	NULL
.	NULL

Degos	NULL
,	NULL
L.	NULL
Annual	NULL
guest	NULL
lecture	NULL
,	NULL
Leukemia	NULL
Research	NULL
Fund	NULL
(	NULL
UK	NULL
)	NULL
:	NULL
differentiation	NULL
therapy	NULL
and	NULL
leukemia	NULL
.	NULL

Leukemia	NULL
(	NULL
Baltimore	NULL
)	NULL
,	NULL
7	NULL
:	NULL
766-772	NULL
,	NULL
1993	NULL
.	NULL

4	NULL
.	NULL

Breitman	NULL
,	NULL
T.	NULL
R.	NULL
,	NULL
Selonick	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
and	NULL
Collins	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

Induction	NULL
of	NULL
differentiation	NULL
of	NULL
the	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
HL60	NULL
)	NULL
by	NULL
retinoic	NULL
acid	NULL
.	NULL

Proc	NULL
.	NULL

Nati	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
77	NULL
;	NULL
2936-2940	NULL
,	NULL
1980	NULL
.	NULL

5	NULL
.	NULL

Castaigne	NULL
,	NULL
S.	NULL
,	NULL
Chomienne	NULL
,	NULL
C.	NULL
,	NULL
Daniel	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Ballerini	NULL
,	NULL
P.	NULL
,	NULL
Berger	NULL
,	NULL
R.	NULL
,	NULL
Fenaux	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Degos	NULL
,	NULL
L.	NULL
All-frans-retinoic	NULL
acid	NULL
as	NULL
a	NULL
differentiation	NULL
therapy	NULL
for	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

1	NULL
.	NULL

Clinical	NULL
results	NULL
.	NULL

Blood	NULL
,	NULL
76	NULL
:	NULL
1704-1709	NULL
,	NULL
1990	NULL
.	NULL

6	NULL
.	NULL

Chomienne	NULL
,	NULL
C.	NULL
,	NULL
Ballerini	NULL
,	NULL
P.	NULL
,	NULL
Balitrand	NULL
,	NULL
N.	NULL
,	NULL
Daniel	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Fenaux	NULL
,	NULL
P.	NULL
Castaigne	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Degos	NULL
,	NULL
L.	NULL
All-frans-retinoic	NULL
acid	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

II	NULL
.	NULL

/n	NULL
vitro	NULL
studies	NULL
.	NULL

Blood	NULL
,	NULL
76	NULL
:	NULL
1710-1717	NULL
,	NULL
1990	NULL
.	NULL

7	NULL
.	NULL

Newmark	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Lupton	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
and	NULL
Young	NULL
,	NULL
C.	NULL
W.	NULL
Butyrate	NULL
as	NULL
a	NULL
differentiating	NULL
agent	NULL
:	NULL
pharmacokinetics	NULL
,	NULL
analogues	NULL
and	NULL
current	NULL
status	NULL
.	NULL

Cancer	NULL
Lett	NULL
.	NULL

,	NULL
78	NULL
:	NULL
1-5	NULL
,	NULL
1994	NULL
.	NULL

8	NULL
.	NULL

Casazza	NULL
,	NULL
A.	NULL
M.	NULL
Anthracyclines	NULL
as	NULL
inducers	NULL
of	NULL
tumor	NULL
cell	NULL
differentiation	NULL
,	NULL
In	NULL
:	NULL
J.	NULL
W.	NULL
Lown	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Bioactive	NULL
Molecules	NULL
,	NULL
Vol	NULL
.	NULL

6	NULL
,	NULL
pp	NULL
.	NULL

715-734	NULL
.	NULL

Amsterdam	NULL
:	NULL
Elsevier	NULL
Science	NULL
Publishers	NULL
,	NULL
B.	NULL
V.	NULL
,	NULL
1988	NULL
.	NULL

9	NULL
.	NULL

Gabbay	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
Grier	NULL
,	NULL
D.	NULL
,	NULL
Fingerie	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Reimer	NULL
,	NULL
R.	NULL
,	NULL
Levy	NULL
,	NULL
R.	NULL
,	NULL
Pearce	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
and	NULL
Wilson	NULL
,	NULL
W.	NULL
D.	NULL
Interaction	NULL
specificity	NULL
of	NULL
the	NULL
anthracyclines	NULL
with	NULL
deoxyribonucleic	NULL
acid	NULL
.	NULL

Biochemistry	NULL
,	NULL
15	NULL
:	NULL
2062-2069	NULL
,	NULL
1976	NULL
.	NULL

10	NULL
.	NULL

Potmesil	NULL
,	NULL
M.	NULL
DNA	NULL
topoisomerase	NULL
!	NULL

I	NULL
as	NULL
intracellular	NULL
target	NULL
in	NULL
anthracycline	NULL
treatment	NULL
of	NULL
cancer	NULL
,	NULL
In	NULL
:	NULL
J.	NULL
W.	NULL
Lown	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Anthracycline	NULL
and	NULL
Anthracenedione-based	NULL
Anticancer	NULL
Agents	NULL
,	NULL
pp	NULL
.	NULL

447-466	NULL
.	NULL

Amsterdam	NULL
:	NULL
Elsevier	NULL
Science	NULL
Publishers	NULL
,	NULL
B.	NULL
V.	NULL
,	NULL
1988	NULL
.	NULL

11	NULL
.	NULL

Trentesaux	NULL
,	NULL
C.	NULL
,	NULL
Gérard	NULL
,	NULL
B.	NULL
,	NULL
Mayeux	NULL
,	NULL
P.	NULL
,	NULL
Jeannesson	NULL
,	NULL
P.	NULL
,	NULL
Jacquot	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Jardiltier	NULL
,	NULL
J-C.	NULL
Differentiating	NULL
activity	NULL
of	NULL
Adriamycin	NULL
in	NULL
human	NULL
erythroleukemic	NULL
cells	NULL
:	NULL
effect	NULL
on	NULL
globin	NULL
and	NULL
heme	NULL
synthesis	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
,	NULL
1012	NULL
;	NULL
161-165	NULL
,	NULL
1989	NULL
.	NULL

12	NULL
.	NULL

Jeannesson	NULL
,	NULL
P.	NULL
,	NULL
Trentesaux	NULL
,	NULL
C.	NULL
,	NULL
Ngo	NULL
Nyoung	NULL
,	NULL
M.	NULL
,	NULL
Mayeux	NULL
,	NULL
P.	NULL
,	NULL
Jacquot	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Jardillier	NULL
,	NULL
J-C	NULL
.	NULL

Induction	NULL
of	NULL
erythropoietin	NULL
receptors	NULL
during	NULL
aclacinomycin-mediated	NULL
erythroid	NULL
differentiation	NULL
of	NULL
K562	NULL
leukemia	NULL
cells	NULL
.	NULL

Leukemia	NULL
(	NULL
Baltimore	NULL
)	NULL
,	NULL
5	NULL
:	NULL
14-18	NULL
,	NULL
1991	NULL
.	NULL

13	NULL
.	NULL

Morceau	NULL
,	NULL
F.	NULL
,	NULL
Aries	NULL
,	NULL
A.	NULL
,	NULL
Lahilil	NULL
,	NULL
R.	NULL
,	NULL
Devy	NULL
,	NULL
L.	NULL
,	NULL
Jardillier	NULL
,	NULL
J-C.	NULL
,	NULL
Jeannesson	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Trentesaux	NULL
,	NULL
C.	NULL
Evidence	NULL
for	NULL
distinct	NULL
regulation	NULL
processes	NULL
in	NULL
the	NULL
aclacinomycin	NULL
and	NULL
doxorubicin-mediated	NULL
differentiation	NULL
of	NULL
human	NULL
erythroleukemic	NULL
cells	NULL
.	NULL

Biochem	NULL
.	NULL

Pharmacol	NULL
.	NULL

,	NULL
51	NULL
:	NULL
839-845	NULL
,	NULL
1996	NULL
.	NULL

14	NULL
.	NULL

Weiss	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
and	NULL
Orkin	NULL
,	NULL
S.	NULL
H.	NULL
GATA	NULL
transcription	NULL
factors	NULL
:	NULL
key	NULL
regulators	NULL
of	NULL
hematopoiesis	NULL
.	NULL

Exp	NULL
.	NULL

Hematol	NULL
.	NULL

,	NULL
23	NULL
:	NULL
99-107	NULL
,	NULL
1995	NULL
.	NULL

15	NULL
.	NULL

Andrews	NULL
,	NULL
N.	NULL
C.	NULL
,	NULL
Erdjument-Bromage	NULL
,	NULL
H.	NULL
,	NULL
Davidson	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
Tempst	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Orkin	NULL
,	NULL
S.	NULL
H.	NULL
Erythroid	NULL
transcription	NULL
factor	NULL
NF-E2	NULL
is	NULL
a	NULL
haematopoietic-specific	NULL
basic-leucine	NULL
zipper	NULL
protein	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
362	NULL
:	NULL
722-728	NULL
,	NULL
1993	NULL
.	NULL

16	NULL
.	NULL

Orkin	NULL
,	NULL
S.	NULL
H.	NULL
Regulation	NULL
of	NULL
globin	NULL
gene	NULL
expression	NULL
in	NULL
erythroid	NULL
cells	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Biochem	NULL
.	NULL

,	NULL
237	NULL
:	NULL
271-281	NULL
,	NULL
1995	NULL
.	NULL

17	NULL
.	NULL

Zon	NULL
,	NULL
L	NULL
.	NULL

|	NULL
.	NULL

,	NULL
Youssoufian	NULL
,	NULL
H.	NULL
,	NULL
Mather	NULL
,	NULL
C.	NULL
,	NULL
Lodish	NULL
,	NULL
H.	NULL
F.	NULL
,	NULL
and	NULL
Orkin	NULL
,	NULL
S.	NULL
H.	NULL
Activation	NULL
of	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
by	NULL
transcription	NULL
factor	NULL
GATA-1	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
88	NULL
:	NULL
10638-10641	NULL
,	NULL
1994	NULL
.	NULL

18	NULL
.	NULL

Mignotte	NULL
,	NULL
V.	NULL
,	NULL
Eleouet	NULL
,	NULL
J-F.	NULL
,	NULL
Raich	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Romeo	NULL
P-H.	NULL
Cis-	NULL
and	NULL
trans-acting	NULL
elements	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
erythroid	NULL
promoter	NULL
of	NULL
the	NULL
human	NULL
porphobilinogen	NULL
deaminase	NULL
gene	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
86	NULL
:	NULL
6548-6552	NULL
,	NULL
1989	NULL
.	NULL

19	NULL
.	NULL

Tsai	NULL
,	NULL
S-F.	NULL
,	NULL
Strauss	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Orkin	NULL
,	NULL
S.	NULL
H.	NULL
Functional	NULL
analysis	NULL
and	NULL
in	NULL
vivo	NULL
footprinting	NULL
implicate	NULL
the	NULL
erythroid	NULL
transcription	NULL
factor	NULL
GATA-1	NULL
as	NULL
a	NULL
positive	NULL
regulator	NULL
of	NULL
its	NULL
own	NULL
promoter	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
5	NULL
:	NULL
919-931	NULL
,	NULL
1991	NULL
.	NULL

20	NULL
.	NULL

Pevny	NULL
,	NULL
L.	NULL
,	NULL
Simon	NULL
,	NULL
L.	NULL
C.	NULL
,	NULL
Robertson	NULL
,	NULL
E.	NULL
,	NULL
Klein	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Tsai	NULL
,	NULL
S-F.	NULL
,	NULL
d'Agati	NULL
,	NULL
V.	NULL
,	NULL
Orkin	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
and	NULL
Costantini	NULL
,	NULL
F.	NULL
Erythroid	NULL
differentiation	NULL
in	NULL
chimaeric	NULL
Cell	NULL
Growth	NULL
&	NULL
Differentiation	NULL
mice	NULL
blocked	NULL
by	NULL
a	NULL
targeted	NULL
mutation	NULL
in	NULL
the	NULL
gene	NULL
for	NULL
transcription	NULL
factor	NULL
GATA-1	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
349	NULL
:	NULL
257-260	NULL
,	NULL
1991	NULL
.	NULL

21	NULL
.	NULL

Andrews	NULL
,	NULL
N.	NULL
C.	NULL
,	NULL
Kotkow	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
Ney	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Erdjument-Bromage	NULL
,	NULL
H.	NULL
,	NULL
Tempst	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Orkin	NULL
S.	NULL
H.	NULL
The	NULL
ubiquitous	NULL
subunit	NULL
of	NULL
erythroid	NULL
transcription	NULL
factor	NULL
NF-E2	NULL
is	NULL
as	NULL
small	NULL
basic-leucine	NULL
zipper	NULL
protein	NULL
related	NULL
to	NULL
the	NULL
v-maf	NULL
oncogene	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
90	NULL
:	NULL
11488-11492	NULL
,	NULL
1993	NULL
.	NULL

22	NULL
.	NULL

Ney	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Sorrentino	NULL
,	NULL
B.	NULL
P.	NULL
,	NULL
Lowrey	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
and	NULL
Nienhuis	NULL
,	NULL
A.	NULL
W.	NULL
Inducibility	NULL
of	NULL
the	NULL
HSI	NULL
enhancer	NULL
depends	NULL
on	NULL
binding	NULL
of	NULL
an	NULL
erythroid	NULL
specific	NULL
nuclear	NULL
protein	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
18	NULL
:	NULL
6011-6017	NULL
,	NULL
1990	NULL
.	NULL

23	NULL
.	NULL

Trentesaux	NULL
,	NULL
C.	NULL
,	NULL
Ngo	NULL
Nyoung	NULL
,	NULL
M.	NULL
,	NULL
Aries	NULL
,	NULL
A.	NULL
,	NULL
Morceau	NULL
,	NULL
F.	NULL
,	NULL
Ronchi	NULL
,	NULL
A.	NULL
,	NULL
Ottolenghi	NULL
,	NULL
S.	NULL
,	NULL
Jardillier	NULL
,	NULL
J-C.	NULL
,	NULL
and	NULL
Jeannesson	NULL
P.	NULL
Increased	NULL
expression	NULL
of	NULL
GATA-1	NULL
and	NULL
NFE-2	NULL
erythroid	NULL
transcription	NULL
factors	NULL
during	NULL
aclacinomycin-mediated	NULL
differentiation	NULL
of	NULL
human	NULL
erythroleukemic	NULL
cells	NULL
.	NULL

Leukemia	NULL
(	NULL
Baltimore	NULL
)	NULL
,	NULL
7	NULL
:	NULL
452-457	NULL
,	NULL
1993	NULL
.	NULL

24	NULL
.	NULL

Brewer	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Ross	NULL
,	NULL
J	NULL
.	NULL

Regulation	NULL
of	NULL
c-myc	NULL
RNA	NULL
stability	NULL
in	NULL
vitro	NULL
by	NULL
a	NULL
labile	NULL
destabilizer	NULL
with	NULL
an	NULL
essential	NULL
nucleic	NULL
acid	NULL
component	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
9	NULL
:	NULL
1996-2006	NULL
,	NULL
1989	NULL
.	NULL

25	NULL
.	NULL

Ngo	NULL
Nyoung	NULL
,	NULL
M.	NULL
,	NULL
Trentesaux	NULL
,	NULL
C.	NULL
,	NULL
Aries	NULL
,	NULL
A.	NULL
,	NULL
Carpentier	NULL
,	NULL
Y.	NULL
,	NULL
Jardillier	NULL
,	NULL
J-C.	NULL
,	NULL
Gorisse	NULL
,	NULL
M-C.	NULL
,	NULL
and	NULL
Jeannesson	NULL
,	NULL
P.	NULL
Effect	NULL
of	NULL
aclacinomycin-doxo-rubicin	NULL
association	NULL
on	NULL
differentiation	NULL
and	NULL
growth	NULL
of	NULL
human	NULL
erythroleukemic	NULL
K562	NULL
cells	NULL
.	NULL

Anticancer	NULL
Res	NULL
.	NULL

,	NULL
14	NULL
:	NULL
1203-1208	NULL
,	NULL
1994	NULL
.	NULL

26	NULL
.	NULL

Aries	NULL
,	NULL
A.	NULL
,	NULL
Trentesaux	NULL
,	NULL
C.	NULL
,	NULL
Ottolenghi	NULL
,	NULL
S.	NULL
,	NULL
Jardillier	NULL
,	NULL
J-C.	NULL
,	NULL
Jeannesson	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Doubeikovski	NULL
,	NULL
A.	NULL
Activation	NULL
of	NULL
erythroid	NULL
specific	NULL
promoters	NULL
during	NULL
anthracycline-induced	NULL
differentiation	NULL
of	NULL
K562	NULL
cells	NULL
.	NULL

Blood	NULL
,	NULL
87	NULL
:	NULL
2885-2890	NULL
,	NULL
1996	NULL
.	NULL

27	NULL
.	NULL

Bridges	NULL
,	NULL
E.	NULL
G.	NULL
,	NULL
Trentesaux	NULL
,	NULL
C.	NULL
,	NULL
Lahiil	NULL
,	NULL
R.	NULL
,	NULL
Spiga	NULL
,	NULL
M-G.	NULL
,	NULL
Jeannesson	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Sommadossi	NULL
,	NULL
J-P.	NULL
3'-Azido-3'-deoxythymidine	NULL
inhibits	NULL
erythroid-specific	NULL
transcription	NULL
factors	NULL
in	NULL
human	NULL
erythroid	NULL
K562	NULL
leukemia	NULL
cells	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Haematol	NULL
.	NULL

,	NULL
56	NULL
:	NULL
62-67	NULL
,	NULL
1996	NULL
.	NULL

28	NULL
.	NULL

Merika	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Orkin	NULL
,	NULL
S.	NULL
H.	NULL
Functional	NULL
synergy	NULL
and	NULL
physical	NULL
interactions	NULL
of	NULL
the	NULL
erythroid	NULL
transcription	NULL
factor	NULL
GATA-1	NULL
with	NULL
the	NULL
Kriuppel	NULL
family	NULL
proteins	NULL
Sp1	NULL
and	NULL
EKLF	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
15	NULL
:	NULL
2437-2447	NULL
,	NULL
1995	NULL
.	NULL

29	NULL
.	NULL

Kawana	NULL
,	NULL
M.	NULL
,	NULL
Lee	NULL
,	NULL
M-E.	NULL
,	NULL
Quertermous	NULL
,	NULL
E	NULL
.	NULL

£	NULL
.	NULL

,	NULL
and	NULL
Quertermous	NULL
,	NULL
T.	NULL
Cooperative	NULL
interaction	NULL
of	NULL
GATA-2	NULL
and	NULL
AP1	NULL
regulates	NULL
transcription	NULL
of	NULL
the	NULL
endothelin-1	NULL
gene	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
15	NULL
:	NULL
4225-4231	NULL
,	NULL
1995	NULL
.	NULL

30	NULL
.	NULL

Gong	NULL
,	NULL
Q.	NULL
,	NULL
and	NULL
Dean	NULL
,	NULL
A.	NULL
Enhancer-dependent	NULL
transcription	NULL
of	NULL
the	NULL
e-globin	NULL
promoter	NULL
requires	NULL
promoter	NULL
bound	NULL
GATA-1	NULL
and	NULL
enhancer-bound	NULL
AP1/NF-E2	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
13	NULL
:	NULL
911-917	NULL
,	NULL
1993	NULL
.	NULL

31	NULL
.	NULL

Ross	NULL
,	NULL
J.	NULL
mRNA	NULL
stability	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Microbiol	NULL
.	NULL

Rev	NULL
.	NULL

,	NULL
59	NULL
:	NULL
423-450	NULL
,	NULL
1995	NULL
.	NULL

32	NULL
.	NULL

Lin	NULL
,	NULL
C-H.	NULL
,	NULL
Palma	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
and	NULL
Solomon	NULL
,	NULL
W.	NULL
B.	NULL
Phorbol	NULL
ester	NULL
induction	NULL
of	NULL
differentiation	NULL
and	NULL
apoptosis	NULL
in	NULL
the	NULL
K562	NULL
cell	NULL
line	NULL
is	NULL
accompanied	NULL
by	NULL
marked	NULL
decreases	NULL
in	NULL
the	NULL
stability	NULL
of	NULL
globin	NULL
mRNAs	NULL
and	NULL
decreases	NULL
in	NULL
the	NULL
steady	NULL
state	NULL
level	NULL
of	NULL
mRNAs	NULL
encoding	NULL
for	NULL
ribosomal	NULL
proteins	NULL
L35	NULL
,	NULL
L31	NULL
,	NULL
L27	NULL
,	NULL
and	NULL
L21	NULL
.	NULL

Cell	NULL
.	NULL

&	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

Res	NULL
.	NULL

,	NULL
40	NULL
:	NULL
13-26	NULL
,	NULL
1994	NULL
.	NULL

33	NULL
.	NULL

Busfield	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Spadaccini	NULL
,	NULL
A.	NULL
,	NULL
Riches	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
Tilbrook	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Klinken	NULL
,	NULL
S.	NULL
P.	NULL
The	NULL
major	NULL
erythroid	NULL
DNA-binding	NULL
protein	NULL
GATA-1	NULL
is	NULL
stimulated	NULL
by	NULL
erythropoietin	NULL
but	NULL
not	NULL
by	NULL
chemical	NULL
inducers	NULL
of	NULL
erythroid	NULL
differentiation	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Biochem	NULL
.	NULL

,	NULL
230	NULL
:	NULL
475-480	NULL
,	NULL
1995	NULL
.	NULL

34	NULL
.	NULL

Tsiftsoglou	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
and	NULL
Wong	NULL
,	NULL
W.	NULL
Molecular	NULL
and	NULL
cellular	NULL
mechanisms	NULL
of	NULL
leukemic	NULL
hemopoietic	NULL
cell	NULL
differentiation	NULL
:	NULL
an	NULL
analysis	NULL
of	NULL
the	NULL
Friend	NULL
system	NULL
.	NULL

Anticancer	NULL
Res	NULL
.	NULL

,	NULL
5	NULL
:	NULL
81-100	NULL
,	NULL
1985	NULL
.	NULL

35	NULL
.	NULL

Ponka	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Schulman	NULL
,	NULL
H.	NULL
M.	NULL
Regulation	NULL
of	NULL
heme	NULL
biosynthesis	NULL
:	NULL
distinct	NULL
regulatory	NULL
features	NULL
in	NULL
erythroid	NULL
cells	NULL
.	NULL

Stem	NULL
Cells	NULL
,	NULL
11	NULL
:	NULL
24-35	NULL
,	NULL
1993	NULL
.	NULL

36	NULL
.	NULL

Profous-Juchelka	NULL
,	NULL
H.	NULL
R.	NULL
,	NULL
Reuben	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
Marks	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Rifkind	NULL
,	NULL
R.	NULL
A.	NULL
Transcriptional	NULL
and	NULL
post-transcriptional	NULL
regulation	NULL
of	NULL
globin	NULL
gene	NULL
accumulation	NULL
in	NULL
murine	NULL
erythroleukemia	NULL
celts	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
3	NULL
:	NULL
229-232	NULL
,	NULL
1983	NULL
.	NULL

37	NULL
.	NULL

Charnay	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Maniatis	NULL
T.	NULL
Transcriptional	NULL
regulation	NULL
of	NULL
globin	NULL
gene	NULL
synthesis	NULL
expression	NULL
in	NULL
the	NULL
human	NULL
erythroid	NULL
cell	NULL
line	NULL
K562	NULL
.	NULL

Science	NULL
(	NULL
Washington	NULL
DC	NULL
)	NULL
,	NULL
220	NULL
:	NULL
1281-1283	NULL
,	NULL
1983	NULL
.	NULL

38	NULL
.	NULL

Warner-Bartnicki	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Murao	NULL
,	NULL
S.	NULL
,	NULL
Collart	NULL
,	NULL
F.	NULL
R.	NULL
,	NULL
and	NULL
Huberman	NULL
,	NULL
E.	NULL
Regulated	NULL
expression	NULL
of	NULL
the	NULL
MRP8	NULL
and	NULL
MRP14	NULL
genes	NULL
in	NULL
human	NULL
promyelocytic	NULL
leukemic	NULL
HL-60	NULL
cells	NULL
treated	NULL
with	NULL
the	NULL
inducing	NULL
agents	NULL
mycophenolic	NULL
acid	NULL
and	NULL
1a,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
.	NULL

Exp	NULL
.	NULL

Cell	NULL
Res	NULL
.	NULL

,	NULL
204	NULL
:	NULL
241-246	NULL
,	NULL
1993	NULL
.	NULL

39	NULL
.	NULL

Morte	NULL
,	NULL
F.	NULL
,	NULL
La	NULL
Verriere	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
and	NULL
Godet	NULL
,	NULL
J.	NULL
Globin	NULL
genes	NULL
are	NULL
actively	NULL
transcribed	NULL
in	NULL
the	NULL
human	NULL
megakaryoblastic	NULL
leukemia	NULL
cell	NULL
line	NULL
MEG-O1	NULL
.	NULL

Blood	NULL
,	NULL
79	NULL
:	NULL
3094-3095	NULL
,	NULL
1992	NULL
.	NULL

1029	NULL

